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Abstract 
Introduction: Rapid changes in cannabis use policy and prevalence, particularly among young 
adults, and the lack of information regarding cannabis harms warrant investigation regarding the 
daily use patterns of cannabis users. Little is known regarding how variability in cannabis use 
frequency and administration method use patterns may be associated with differential acute 
cannabis-related health effects (i.e., subjective intoxication and respiratory symptoms). The 
purpose of the study was to characterize daily and weekly cannabis use patterns and associated 
cannabis-related intoxication and respiratory symptoms and test the interactions of cannabis use 
frequency and cannabis administration method use on cannabis-related intoxication and 
respiratory symptoms among young adult heavy cannabis users  
Methods: Participants included 27 young adults who used cannabis at least 5 days per week and 
were 18 to 25 years old. Participants were asked to complete two weeks of surveys sent to their 
cell phones three times daily. Assessments included cannabis use frequency (measured in hits), 
cannabis administration method use (classified into two groups: combusted methods [joint, blunt, 
bowl/pipe, bong] and combination methods [any of the previously listed methods and vaporizer 
or dab]), and cannabis-related intoxication (mental and physical high) and respiratory symptoms 
(coughing/wheezing, throat irritation, and phlegm/chest mucus). Data were analyzed using linear 
mixed models, a two-way analysis of variance, and a two-way analysis of covariance. All 
analyses were conducted using SPSS (p<0.05).  
Results: Cannabis hits frequency, number of cannabis administration methods used, and 
cannabis-related intoxication were highest or most severe in the evenings. Day of week effects 
were not observed for any outcomes. High frequency cannabis users reported significantly higher 
cannabis-related intoxication symptoms compared to low frequency users. Among only those in 
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the high frequency cannabis use group, combination administration method users reported 
significantly higher intoxication compared to combusted administration method users. No 
differences in respiratory symptoms among cannabis administration method sub-groups or use 
frequency sub-groups were observed.  
Conclusions: Current study results inform interventionists, cannabis users, public health 
officials, and policy makers with the goal of reducing the negative health effects associated with 
cannabis use. Future research should measure cannabis-related intoxication effects in various 
ways to more fully understand cannabis impairment. The use of biological and behavioral 
measures in clinical and natural settings would aid this goal. Research on respiratory symptoms 
and cannabis use would benefit from the development of validated instruments, which measure 
acute cannabis-related respiratory symptoms. Overall, current study results act as a foundation 
for future researchers to examine further cannabis-related health effects among heavy cannabis 
users.  
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Introduction 
Overview and Motivation for Study 
 Cannabis, a well-known drug class used for recreational and medicinal purposes, is the 
most frequently used illegal drug in the United States (US; CBHSQ, 2018). Prevalence trends 
demonstrate that cannabis use has increased among young adults (CBHSQ, 2018). In 2015, 
19.8% of young adults aged 18-25 used cannabis in the past month, which increased to 20.8% in 
2016 and increased to 22.1% in 2017 (CBHSQ, 2018). Importantly, as of 2017, young adults 
aged 21-24 used cannabis daily more than any other age group (9%), the highest rate of daily use 
since 1982 (Schulenberg et al., 2018). At the same time, cannabis policies for recreational and 
medicinal use are rapidly evolving in the US (National Conference of State Legislatures, 2018a, 
2018b). These changes in cannabis use and policies warrant investigation on the daily use 
patterns of cannabis users to prevent negative health consequences associated with cannabis use. 
Cannabis use can be associated with harmful abuse and dependence behaviors; however, 
cannabis use is also associated with therapeutic effects. It is unclear which cannabis use patterns 
are the most harmful to users. Areas for exploration on cannabis-related harms include effects 
associated with varying cannabis use frequency and administration method (i.e., combusted 
versus non-combusted method) use. Differential levels of cannabis use frequency and use of 
individual or combination cannabis administration methods may produce markedly different 
cannabis-related health symptoms including intoxication and negative respiratory effects. 
Importantly, these latter health symptoms could result in immediate as well as long-term 
negative health consequences. The proposed study aims to characterize patterns of cannabis use 
frequency and cannabis administration method use, as well as their effects and interaction on 
health-related symptoms among young adults in the US.  
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Cannabis: Cannabinoids, Cannabis Forms, and Cannabis Administration Methods  
Cannabis, frequently known as marijuana, is a plant, which can grow as several different 
species (i.e., strains). The three most common species are Cannabis sativa, Cannabis indica, and 
Cannabis ruderalis (Sawler et al., 2015). Many varieties of cannabis are sexually propagated 
hybrids, which contain genes from different species (Emboden, 1974). Each cannabis plant 
and/or variety has a unique cannabinoid profile, which can determine its legal status (i.e., an 
agricultural hemp product vs. an illegal drug; Russo & Marcu, 2017; U.S. Food and Drug 
Administration, 2019a). Cannabinoids are a class of chemical compounds, which are found 
endogenously (as anandamide) and exogenously (such as in a cannabis plant). These 
cannabinoids interact with specific cannabinoid receptors (CB1 and CB2) in the brain and other 
areas of the body (Ameri, 1999; El-Alfy et al., 2010; Mehmedic et al., 2010; Nguyen et al., 
2017). Of import, CB1 receptors are mainly concentrated in the brain, while CB2 receptors are 
located primarily in immune cells (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990; 
Munro, Thomas, & Abu-Shaar, 1993).  
Over 100 cannabinoids have been identified in cannabis plants; however, the most 
common types include Δ9-tetrahydrocannabinol (THC) and cannabidiol (Ameri, 1999; Lafaye, 
Karila, Blecha, & Benyamina, 2017; Russo & Marcu, 2017). THC is a volatile viscous oil that is 
highly lipophilic (Sharma, Murthy, & Bharath, 2012) and is the primary psychoactive 
cannabinoid in cannabis plants, which is associated with a subjective intoxication or “high” (M. 
J. E. Loflin et al., 2017; Sharma et al., 2012). The pleasurable and rewarding effects of THC 
have been the primary reasons for the widespread use and abuse of cannabis (Sharma et al., 
2012). It is important to note that CBD popularity and use is rising due to recent changes in 
policies regarding the sale and production of this compound (Corroon & Kight, 2018; Corroon & 
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Phillips, 2018). Previous to 2018, cannabis with any amount of THC was deemed federally 
illegal to grow, consume, or possess; however, the Agriculture Improvement Act of 2018 revised 
federal laws to allow the growth, consumption, and possession of cannabis with less than 0.3% 
THC content (U.S. Senate Committee on Agriculture Nutrition and Forestry, 2018). This type of 
cannabis is known as hemp. Hemp is grown and consumed primarily for its high CBD content, 
but hemp has other purposes including textiles, paper, and construction (Small & Marcus, 2002). 
For the purposes of this dissertation, hemp is not a focus, and when the term “cannabis” is used, 
we refer to products with greater than 0.3% THC content.  
THC concentration in cannabis has increased over time. In the 1980s, average THC 
concentration from seized dried cannabis products was 3% and has increased to approximately 
17% in 2017 (Chandra et al., 2019; ElSohly et al., 2016). Highly concentrated THC products are 
becoming more popular in the form of cannabis concentrates (e.g., hash oil, dabs; Cavazos-Rehg 
et al., 2018; Daniulaityte et al., 2017; M. Loflin & Earleywine, 2014; Zhang, Zheng, Zeng, & 
Leischow, 2016). Reports of THC content in cannabis concentrates indicate an average THC 
content of 55.7% in 2017, and other reports indicate THC content up to 80% (Chandra et al., 
2019; Stogner & Miller, 2015).  
This evolution of increased THC concentrations in cannabis products has occurred in 
tandem with changes in the means to consume cannabis (i.e., administration methods; Russell, 
Rueda, Room, Tyndall, & Fischer, 2018). Many forms of cannabis (e.g., dried, concentrate, 
edible, etc.) are consumed via many various administration methods, which complicates study 
and scientific terminology in this area. In terms of administration methods, cannabis can be 
consumed in many ways including joints, blunts, bongs, bowls/pipes, vaporizers, 
concentrate/“dab” rigs, and edibles, which may be associated with differential patterns of use and 
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health effects (see Figures 1 and 2; Rudy, 2018). Joints consist of dried cannabis wrapped in a 
cigarette rolling paper, and blunts consist of dried cannabis wrapped in tobacco leaves/hollowed 
tobacco cigars (Schauer, King, Bunnell, Promoff, & McAfee, 2016). Bongs and bowls/pipes are 
devices, often made of glass, in which dried or concentrated cannabis is placed in a concave 
bowl (see Figure 1, Panel A; Kelly, 2005). Joints, blunts, bongs, and bowls/pipes are used by 
directly igniting cannabis and subsequently inhaling the emitted smoke; therefore, these 
administration methods are considered combusted administration methods. Vaporizers or 
electronic cigarettes (e-cigarettes) are devices, which contain a battery, heating element, or 
atomizer, which when activated, warms cannabis-containing material (dried, concentrated, or 
liquid form) to a temperature that produces an aerosol to be inhaled (see Figure 1, Panel B; Lee, 
Crosier, Borodovsky, Sargent, & Budney, 2016). For the purposes of this dissertation, the term 
“vaporizer” will be used. Concentrate/“dab” rigs (i.e., dabs) are devices that use a blowtorch or 
electronic heating element to indirectly heat cannabis-containing material (typically 
concentrated) to be inhaled (see Figure 2; Raber, Elzinga, & Kaplan, 2015). Finally, edibles are 
food products that are made with cannabis (in many forms). Unlike combusted administration 
methods, vaporizers, concentrate/”dab” rigs, and edibles are not consumed through directly 
lighting cannabis on fire; therefore, these methods are considered “other” administration 
methods.  
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Figure 1. Devices for cannabis consumption. Panel A displays typical glass devices including a 
bong, concentrate/“dab” rig, and bowl/pipe. Panel B displays electronic devices including a dry 
material vaporizer and an electronic cigarette where cannabis-containing liquid would be loaded.   
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Figure 2. A cannabis concentrate/”dab” rig. A cannabis concentrate/”dab” rig typically includes 
a dome, which helps contain the cannabis emissions, and a nail (where the concentrate 
preparation is placed).  
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Clinical Effects of Cannabis Use 
Despite the range of cannabis administration methods available to consume cannabis-
containing products, a large amount of clinical research to date has focused on the effects of 
combusted dried cannabis (usually in the form of joints) and the effects of the primary 
psychoactive cannabinoid, THC (Heishman, Huestis, Henningfield, & Cone, 1990; Russell et al., 
2018); although see (Millar, Stone, Yates, & O'Sullivan, 2018 for CBD review). In terms of 
speed of drug delivery, THC can be detected in blood plasma within seconds after inhalation via 
combusted administration methods (Grotenhermen, 2003; Sharma et al., 2012). A recent study of 
vaporized cannabis among infrequent cannabis users indicated that use of Volcano vaporizer 
device (with dried cannabis) resulted in higher peak blood-level THC concentrations compared 
to when the same THC doses were consumed using a pipe and lighter (Spindle et al., 2018).  
Oral cannabis consumption results in a slower delivery of THC and longer time to peak plasma 
concentration compared to smoked and vaporized cannabis (Grotenhermen, 2003; Newmeyer et 
al., 2016). Of import, THC is rapidly metabolized to 11-hydroxy-delta-9-THC, which is a 
pharmacologically active metabolite with a duration of action of 4-6 hours (Advokat, 2014). The 
speed of delivery and associated administration method, dose of THC and its metabolites as well 
as other relevant cannabinoids influence the onset and range of clinical effects observed for 
cannabis. Of those with the highest applicability for the proposed project include subjective (e.g., 
mood, intoxication) effects, respiratory effects, other adverse effects (e.g., impaired 
memory/performance), and therapeutic effects.  
Subjective effects of cannabis use are generally classified into two categories: positive 
and negative (Green, Kavanagh, & Young, 2003; Zeiger et al., 2012). Positive subjective effects 
of cannabis use include increased euphoria, relaxation, creativity, sociability, and energy, and 
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improved mood (Zeiger et al., 2012). Negative subjective effects of cannabis use include 
increased depression, anxiety, paranoia, hallucinations, feelings of guilt and laziness, drowsiness, 
and inability to concentrate (Zeiger et al., 2012). There are also other types of subjective effects, 
which can be classified into either category. These effects include increased appetite, 
talkativeness, and intoxication (Green et al., 2003; Zeiger et al., 2012). Cannabis intoxication is 
often indexed via the subjective item “high” or “stoned,” which asks participants to rate how 
they feel at that moment (Bidwell et al., 2018; Wachtel, ElSohly, Ross, Ambre, & de Wit, 2002). 
Subjective ratings of “high” consistently have been positively associated with THC blood levels 
delivered via combusted cannabis in controlled settings (Bidwell et al., 2018; Heishman et al., 
1990; Schwope, Bosker, Ramaekers, Gorelick, & Huestis, 2012). Cannabis intoxication can also 
be measured by assessing physical or body intoxication and mental intoxication (e.g., “How 
mentally stoned do you feel right now?”; Bidwell et al., 2018). Much like these broader 
intoxication measures, available data suggests that subjective ratings of physical and mental 
intoxication are strongly correlated with blood THC levels (rs>0.60, ps<0.05; Bidwell et al., 
2018). Appropriate measures of acute cannabis intoxication are critical due to the associated 
health consequences including increased risk of traffic accidents and decreased inhibition leading 
to risk-taking behavior (Oomen, van Hell, & Bossong, 2018; Rogeberg & Elvik, 2016).  
Another important class of clinical effects of cannabis relates to respiratory effects, which 
have been the subject of much previous work in this area (Howden & Naughton, 2011; 
Martinasek, McGrogan, & Maysonet, 2016; National Academies of Sciences, 2017; Tetrault et 
al., 2007) considering the majority of cannabis is consumed via administration methods requiring 
combustion and/or inhalation (Russell et al., 2018). Like tobacco smoke, cannabis smoke 
contains particulate matter and carcinogens but the concentrations and constituents of each vary 
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dramatically (Moir et al., 2008). Previous and recent systematic reviews including one performed 
by the National Academies of Sciences (2017) support the idea that cannabis use has negative 
respiratory effects. Chronic cannabis use has been associated with increased risk for cough, 
sputum production, wheezing, and dyspena (shortness of breath; Ghasemiesfe et al., 2018). 
Effects of chronic cannabis use on development of lung cancer, pulmonary function, and chronic 
obstructive lung disease are not conclusive, but some positive associations have been observed 
among studies linking cannabis use to these negative health outcomes (Ghasemiesfe et al., 2018; 
Martinasek et al., 2016). Importantly controlling for and/or determining the impact of concurrent 
tobacco use and administration method use involving cannabis/tobacco co-use (i.e., blunts) on 
the study of cannabis respiratory effects remains challenging for researchers (Tashkin & Roth, 
2019). Adding to this body of literature is some support for an association between cannabis use 
and improved airway dynamics under specific acute use conditions (National Academies of 
Sciences, 2017), but attempts to harness this effect for clinical purposes have been ineffective, 
likely due to the negative respiratory effects of other constituents present in cannabis smoke 
(Tashkin & Roth, 2019). Early evidence from cross-sectional and clinical trial data sources 
suggests cannabis consumption with vaporizers may reduce negative respiratory symptoms 
and/or improve pulmonary function (Earleywine & Barnwell, 2007; Sexton, Cuttler, Finnell, & 
Mischley, 2016; Van Dam & Earleywine, 2010). Contrary to these reports has been a recent 
surge in e-cigarette or vaping product use-associated lung injury (known as EVALI) cases and 
deaths in the US (1,299 cases and 26 deaths as of October 8, 2019) from devices containing THC 
and/or nicotine products (Centers for Disease Control and Prevention, 2019). Specific chemical 
exposures associated with these negative effects is unknown at this time (Centers for Disease 
Control and Prevention, 2019). Data regarding respiratory effects associated with use of 
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rigs/dabs (used to heat cannabis concentrates) is limited, but at least two case reports of 
respiratory failure and one for severe pneumonitis have been reported in the literature (Anderson 
& Zechar, 2019; McMahon, Bhatt, Stahlmann, & Philip, 2016). These early studies should be 
interpreted carefully considering the little information known about cannabis vaporizer and 
concentrate use. As has been shown with tobacco products (U.S. Department of Health and 
Human Services, 2014), respiratory and other health effects may differ dramatically depending 
on characteristics of the cannabis administration method and patterns of cannabis use. Future 
research should aim to understand differences in respiratory effects between these cannabis 
administration methods acutely and over time.  
Other adverse health effects of cannabis use include a range of physiological effects, 
cognitive process effects, and the development of mental health conditions. For example, 
cannabis has been linked with suppression of antibody production in the immune system (Rieder, 
Chauhan, Singh, Nagarkatti, & Nagarkatti, 2010) as well as decrease in several inflammatory 
cytokines (National Academies of Sciences, 2017). Acutely, cannabis increases heart rate and 
blood pressure via increased sympathetic nervous system activation, and these effects have been 
linked to (but not conclusively associated with) greater risk for triggering myocardial infarctions 
(Franz & Frishman, 2016; National Academies of Sciences, 2017). Cognitive processes impaired 
by cannabis use acutely and some cases residually or chronically include working memory, 
inhibition/impulsivity, attention/concentration, and reaction time (Ameri, 1999; Crean, Crane, & 
Mason, 2011; Sharma et al., 2012; Volkow, Baler, Compton, & Weiss, 2014). Similar to 
intoxication, many of these cognitive impairments are often associated with adverse behavioral 
outcomes including poor academic performance, impaired driving, and increased likelihood for 
hospitalization (Arria, Caldeira, Bugbee, Vincent, & O'Grady, 2015; Gerberich et al., 2003; 
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Rogeberg & Elvik, 2016; Sewell, Poling, & Sofuoglu, 2009). Importantly, cannabis use among 
youth and young adults can affect the developing brain resulting in impaired neuronal 
connectivity as well as reduced volumes in some brain areas such as the hippocampus as 
demonstrated by neuroimaging studies performed on long-term cannabis users (Filbey & 
Yezhuvath, 2013; Jacobus & Tapert, 2014; Zalesky et al., 2012). Results highlight the impact of 
earlier age of onset on neurological and cognitive effects of cannabis use (Volkow et al., 2014).  
Cannabis use is also associated with development of mental disorders including substance use 
disorders (other than cannabis use disorder) as well as risk for identifying with a mood disorder 
such as anxiety or depression and psychotic disorder (National Academies of Sciences, 2017). 
Critically the directionality of relationships between cannabis use and mood/psychotic disorders 
remains unclear (National Academies of Sciences, 2017; Volkow et al., 2014). Last but not least, 
heavy cannabis use frequency and earlier age of cannabis use onset have been associated with 
the development of problematic cannabis use, which include characteristics used to define 
cannabis use disorder by the American Psychological Association (see Trends in Cannabis Use 
and Dependence; National Academies of Sciences, 2017). 
In addition to these subjective, respiratory, and other adverse effects, cannabis use is also 
associated with a menagerie of therapeutic health effects (National Academies of Sciences, 
2017). In terms of the strongest levels of evidence, cannabis use has been shown to produce 
analgesic (Rivera-Olmos & Parra-Bernal, 2016; van de Donk et al., 2019) and anticonvulsive 
effects (Carlini & Cunha, 1981; Schrot & Hubbard, 2016). Cannabis use can alleviate symptoms 
and complications with Alzheimer’s disease, multiple sclerosis, and epilepsy (Karl, Garner, & 
Cheng, 2016; Leo, Russo, & Elia, 2016; Lippiello et al., 2016; Patti et al., 2016). Many of these 
effects may underlie the increasing use of cannabis as well as individual cannabinoids as a 
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medical treatment (Dronabinol, synthetic form of THC; Epidiolex, plant-derived purified form of 
CBD; U.S. Department of Health and Human Services, 2004; U.S. Food and Drug 
Administration, 2018) or via self-diagnosis in US states with legalized recreational cannabis 
(Sarvet et al., 2018). Importantly, very few of cannabis/cannabinoid-based products are FDA-
approved drugs, but due to the changing regulatory environment in the US and elsewhere, large 
numbers of cannabis-containing dietary supplements are emerging with little empirical data to 
support their use (U.S. Food and Drug Administration, 2019b).   
Trends in Cannabis Use and Dependence 
 Trends in national past 30-day cannabis use rates and cannabis dependence have been 
monitored for nearly 50 years (U.S. Substance Abuse and Mental Health Data Archive, 2019). 
Current (past 30-day) cannabis use among US adults aged 18 and older was 9.9% in 2017 
(CBHSQ, 2018). Using data from the same source, among US adults aged 18-25, current 
cannabis use was 20.8% in 2016 and increased to 22.1% in 2017 (CBHSQ, 2018). In contrast, 
7.9% of US adults aged 26 and older used cannabis in the past month in 2017 (CBHSQ, 2018). 
Among young adult (aged 18-25) past month cannabis users, 44.3% used cannabis daily or 
almost daily in 2017, which is higher than any other age group (CBHSQ, 2018). One strength of 
obtaining cannabis use rates via the aforementioned national US datasets is the ability to monitor 
yearly changes in lifetime, past year, past month, and daily cannabis use. However, a limitation 
to this type of data collection is the lack of fine-detail information about cannabis use patterns 
including the frequency of use per day or week (Asbridge, Duff, Marsh, & Erickson, 2014). 
As defined by the American Psychiatric Association Diagnostic and Statistical Manual 
for Mental Disorders, fifth edition (DSM-5), cannabis substance use disorder is classified by the 
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presence of two or more specified criteria occurring within a 12-month period  including 1) 
tolerance, 2) withdrawal, 3) a great deal of time spent in activities necessary to obtain, use, or 
recover from the effects of cannabis, 4) persistent desire or unsuccessful efforts to cut down or 
control cannabis use, 5) often taken in larger amounts over time, 6) continued use despite social 
or interpersonal problems caused by the effects of cannabis use, 7) important activities reduced 
due to cannabis use, 8) recurrent substance use in places which are physically dangerous, 9) 
persistent cannabis use despite knowledge of harms, 10) cannabis use which results in failure to 
conduct personal obligations, and 11) craving or strong urges to use cannabis (APA, 2013). 
Many of the nationally representative monitoring systems have not transitioned to this current 
definition and instead utilize substance use dependence and abuse classification guidelines from 
the Diagnostic Statistical Manual for Mental Disorders, fourth edition (DSM-IV). The newer 
cannabis use disorder definition incorporates all of the previous cannabis dependence use 
criterion and the majority of the abuse criterion with two exceptions: one addition – craving or 
strong urges to use the substance – and one removal – substance-related legal problems 
(BehaveNet, 2016). 
Due to the recent changes in diagnostic criterion, the available data collapses cannabis 
use and abuse categories in order to identify the prevalence of cannabis use disorder. Although 
current cannabis use has increased, the prevalence of cannabis use disorders among those aged 
12 and older has decreased from 1.8% in 2002 to 1.5% in 2017 (CBHSQ, 2018). For young 
adults (aged 18-25), cannabis use disorder decreased from 6.0% in 2002 to 5.2% in 2017 
(CBHSQ, 2018). Among US adults, cannabis use disorder slightly decreased from 1.5% in 2002 
to 1.4% in 2017 (CBHSQ, 2018). Taken together, national data across multiple groups suggest 
that overall cannabis use is increasing moderately while the prevalence of cannabis use disorders 
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has experienced little change over the same time period. These discrepancies in cannabis use and 
disorder incidence may be due to changes in substance disorder criteria, lagged effects in 
disorder development, and/or poor measurement of cannabis use rates. Continued and more 
detailed surveillance is essential to better understand these trends.   
Influence of Cannabis Policy Changes on Prevalence 
Changes in cannabis policies may also be driving changes in cannabis use and disorder 
prevalence. Although cannabis remains illegal under the US federal government, some state 
governments have alternative laws regarding cannabis use and cultivation. California was the 
first state to legalize the use, possession, and production of cannabis for medicinal reasons in 
1996 (National Conference of State Legislatures, 2018b), and since then, 34 states, Washington, 
DC, and 3 US territories have legalized cannabis for medicinal use (National Conference of State 
Legislatures, 2018b). In 2012, Colorado was the first state to legalize cannabis for recreational 
use (National Conference of State Legislatures, 2018a), and since then, 10 states and 
Washington, DC legalized cannabis for recreational use (National Conference of State 
Legislatures, 2018a). These laws allow for the use, possession, and production of cannabis to any 
adult over the age of 21 (Marijuana Policy Project, 2019). Specifically in the state of Virginia, 
the possession, sale, and use of cannabis remains illegal to anyone, regardless of age (The 
National Organization for the Reform of Marijuana Laws, 2019). However, the use of CBD and 
hemp products is legal in Virginia, as is consistent with federal laws on hemp-derived CBD (see 
Cannabis: Cannabinoids, Cannabis Forms, and Cannabis Administration Methods; U.S. 
Senate Committee on Agriculture Nutrition and Forestry, 2018). Changes in cannabis policies 
inevitably invoke other consequences including changes in cannabis use patterns. 
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Several studies have evaluated changes in cannabis use prevalence due to cannabis 
legalization in US states. Previous research in this area focuses mostly on changes in cannabis 
use due to changes in medicinal cannabis policies, and there is limited research on how the 
legalization of recreational cannabis impacts cannabis use. There are two known published 
studies on the impact of recreational cannabis policy changes on cannabis use among youth. A 
secondary data analysis of cannabis use among 8th, 10th, and 12th grade youth in Washington 
state pre- and post- cannabis legalization was conducted (Dilley et al., 2019). Results indicated 
that after recreational cannabis legalization, cannabis use did not change among youth in 8th and 
10th grades and decreased among youth in 12th grade compared to pre-legalization (legal market 
opened in 2014; (Dilley et al., 2019). However, according to a secondary data analysis of a 
national dataset (Monitoring the Future) of 8th, 10th, and 12th graders in Washington state, 
cannabis use increased among 8th and 10th graders post-legalization, but changes in cannabis use 
were not found among 12th graders (Cerda et al., 2017). Interestingly, among 8th, 10th, and 12th 
graders in Colorado, no changes in cannabis use were found between pre-legalization and post-
legalization (Cerda et al., 2017). These studies indicate a discrepancy on the impact of 
recreational cannabis legalization on cannabis use rates among youth, and less is known 
regarding the impact of changes in cannabis policies among other high risk groups such as young 
adults.  
There are no known published studies that have evaluated the impact of recreational 
policy changes on cannabis use among adults, and few studies have identified the relationship 
between medicinal cannabis policy changes and adult cannabis use. Several cross-sectional 
studies have identified higher rates of adult cannabis use in states with medicinal cannabis 
legalization compared to states without medicinal cannabis legalization (Cerda, Wall, Keyes, 
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Galea, & Hasin, 2012; Wen, Hockenberry, & Cummings, 2015). A study conducted in 2017 
analyzed cannabis use and cannabis use disorder from three nationally representative 
longitudinal surveys among US adults (D. S. Hasin et al., 2017). The study compared states with 
and without medicinal cannabis legislation during each of the survey periods. Results indicated 
that the legalization of medicinal cannabis was associated with a higher prevalence of cannabis 
use and cannabis use disorder compared to states without medicinal cannabis laws across all 
survey time periods (D. S. Hasin et al., 2017). Importantly, follow-up analyses using the same 
dataset indicated that daily/near daily cannabis use also increased following medicinal cannabis 
legalization compared to states without medicinal cannabis laws (D. Hasin et al., 2017). In sum, 
although changes in medicinal cannabis laws indicate various findings among adolescent 
cannabis use, data indicate that, for adults, cannabis use and cannabis use disorder prevalence 
increase in states with medicinal cannabis laws. 
Characterizing Cannabis Administration Method Use 
Although most previous research with cannabis has focused on the use of joints or other 
combustible administration methods, there has been a proliferation in use of other cannabis 
administration methods in the US. In a study of US adult daily cannabis users in 2012, more than 
half reported weekly usual use of joints (53%), blunts (51%), pipes (55%), or bongs (32%) with 
fewer individuals endorsing use of vaporizers (6%; Hughes et al., 2014). In 2014, among US 
adults who used cannabis in the past 30 days, bowls/pipes were the most popular method of 
administration (49.5%), followed by joints (49.2%), bongs (21.7%), blunts (20.3%), edibles 
(16.1%), and vaporizers (7.6%; Schauer et al., 2016). Available data suggest similar trends exist 
for young adult cannabis users – combustible methods are most popular, followed by edibles and 
vaporizer use. Among a sample of US young adult past 30-day cannabis users assessed in 2017, 
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blunts and bongs were the most popular cannabis administration methods (54.8%, 54.8%), 
followed by bowls/pipes (50.0%), joints (40.0%), edibles (27.4%), and vaporizers or 
concentrate/”dab” rig use (19.2%; Rudy, 2018).  
Data regarding the type and frequency of cannabis administration method use is limited, 
but previous work and my own has indicated that young adult heavy cannabis users regularly 
report using multiple cannabis administration methods (≥3 methods per month) from data 
measured prospectively (Hughes et al., 2014) as well as retrospectively (Rudy, 2018). In 2014, 
among a nationally representative sample of US adults who used cannabis in the past 30 days, 
58.8% reported using one cannabis administration method, 22.4% reported using 2 cannabis 
administration methods, and 18.8% of cannabis users indicated using 3 or more cannabis 
administration methods in the past 30 days (Schauer et al., 2016). However, a gap remains 
regarding how the frequency of these methods may fluctuate over time and how these methods 
may influence health effects in young adult heavy cannabis users. 
Many previous studies consider cannabis users as homogenous (i.e., equating joint 
smokers to those who consume only edibles); however, my own research has indicated that 
cannabis users are heterogeneous in terms of their frequency of cannabis use and cannabis 
administration methods used. In a sample of young adult past 30-day cannabis users, four latent 
classes of cannabis users defined by frequency of cannabis administration use were identified 
(Rudy, 2018). The two largest classes (over 84% of the sample) were characterized by high 
probabilities of using either blunts or bongs between 1-10 times per month. The two smallest 
classes (4-13% of the sample) were characterized by high probabilities of using all methods of 
cannabis administration and for some, at higher frequencies (10+ times per month). More 
specifically, the third class was characterized by high probabilities of using edibles and 
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concentrate/”dab” rigs and vaporizers, while the fourth (smallest) class was characterized by a 
high probability of using edibles but a low probability of using concentrate/”dab” rigs and 
vaporizers. These data highlight critical subgroups among current cannabis users that may 
benefit from tailored intervention. The two classes who used multiple cannabis administration 
methods at higher frequencies are likely at higher risk for dependence and possibly health related 
consequences compared to other types of cannabis users.  
Interactions between Cannabis Use Frequency, Administration Method, and Health Effects  
As stated previously, research suggests that higher cannabis use frequency is associated 
with increased intoxication and respiratory symptoms compared to lower cannabis use frequency 
(Hall & Degenhardt, 2009; Hughes et al., 2014; Walden & Earleywine, 2008). However, less is 
known about how cannabis use frequency of specific cannabis administration methods may 
influence these health effects. Vaporizer and concentrate/”dab” rig use has been associated with 
greater reports of intoxication, which is likely due to the high-THC potency cannabis often used 
with these methods (Lee et al., 2016; M. Loflin & Earleywine, 2014). In 2014-2015, an online 
survey was administered to US adult cannabis users (Lee et al., 2016). Among those who had 
reported lifetime vaporizer use, over half indicated higher intoxication when using a vaporizer 
with cannabis compared to smoking cannabis (Lee et al., 2016). Likewise, in an online survey 
administered in 2014 among US adult concentrate/dab users, over a third of concentrate/dab 
users reported stronger intoxication from concentrates/dabs compared to other cannabis 
administration methods (M. Loflin & Earleywine, 2014). Edible use has also been associated 
with greater intoxication due, in part, to the accidental consumption of more than intended and 
the metabolism of THC through the gastrointestinal tract (Barrus et al., 2016; Hudak, Severn, & 
Nordstrom, 2015; Lewis, Fleeger, Judge, Riley, & Jones, 2020). Still unknown, these studies did 
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not reveal how frequency of use interacted with intoxication. The interaction between cannabis 
administration method, frequency of use, and intoxication symptoms remains unclear. Direct 
comparison of subjective intoxication by cannabis administration method and frequency has yet 
to be explored in a controlled or naturalistic setting, limiting knowledge in this area.  
As stated previously, evidence regarding respiratory outcomes has typically focused on 
joints, but less in known regarding how non-combusted and other methods of administration 
affect respiratory symptoms. Moreover, little data is available that examines how cannabis use 
frequency affects the relationship between administration method and respiratory symptoms. In a 
systematic review of the respiratory effects of inhaled cannabis conducted in 2016, many studies 
indicated that cannabis users have reported wheezing, shortness of breath, cough, and phlegm 
from their use of inhaled cannabis products (Martinasek et al., 2016). Several previous studies 
indicate that cannabis use with a vaporizer decreased negative respiratory symptoms while there 
has been an increase in lung-related injuries related to vaporizer use sometimes but not all the 
time with THC-containing liquids. In a cross-sectional online survey study of US adult cannabis 
users conducted in 2007, participants reported their usual symptoms of coughing, wheezing, 
shortness of breath, phlegm, and tightness of chest, in addition to vaporizer use and cigarette use 
(Earleywine & Barnwell, 2007). Results indicated that cannabis and cigarette use were 
associated with increased respiratory symptoms, but this effect was lower among vaporizer users 
(Earleywine & Barnwell, 2007). In 2014, an online, cross-sectional survey was administered to 
an international sample of cannabis users (Malouff, Rooke, & Copeland, 2014). Qualitative 
results indicated that over half the sample used cannabis with a vaporizer for its perceived health 
benefits including “felt easier on my lungs” (p. 128) and “no more coughing up dust and tar” 
(Malouff et al., 2014, p.128). Unlike the reported respiratory effects of vaporizer use, two case 
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reports of concentrate/dab use resulted in severe pneumonitis (Anderson & Zechar, 2019; 
McMahon et al., 2016). In sum, these studies indicate that using cannabis with a vaporizer may 
decrease respiratory symptoms and using cannabis via concentrates/dabs may exacerbate 
respiratory symptoms, but further research is needed to understand how use frequency may 
interact with this relationship.  
Given this limited evidence, it is likely that high frequency use of cannabis administration 
methods involving concentrated cannabis (vaporizer and concentrate/”dab” rigs) may produce 
the highest intoxication symptoms, and combusted administration method (blunts, joints, bongs, 
etc.) use at high frequencies may be associated with more negative respiratory symptoms relative 
to other frequency/administration method sub-groups. To best assess these proposed 
relationships, a study design/data collection method must be selected carefully to maximize 
ecological validity (cannabis use under naturalistic conditions), reliability (due to the complex 
behavior patterns of cannabis use) and participant protection (due to specific legal restrictions 
regarding cannabis).  
Methods to Understand Cannabis Use Patterns and Associated Factors 
Ecological momentary assessment (EMA) is a particularly optimal method to understand 
the interaction of cannabis use frequency, cannabis administration methods, and cannabis-related 
health symptoms that involves frequent, ‘in the moment’ naturalistic data collection (Shiffman, 
2009). The use of EMA minimizes the likelihood of recall bias, improves ecological validity, and 
provides data regarding within-person variability (Collins, Kashdan, & Gollnisch, 2003; M. M. 
Phillips, Phillips, Lalonde, & Dykema, 2014; Shiffman, 2009). EMA can be measured via 
several mechanisms that can be cell-phone or app-based including automated text messages 
wherein participants answer daily questions through a web-link using their phone. Text message 
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based-EMA provides privacy for sensitive data due to the automatic recording of data to a secure 
website compared to other forms of EMA using paper diaries. 
 Previous EMA studies among cannabis users measured the time course of cannabis quit 
attempts (Buckner, Zvolensky, & Ecker, 2013), cannabis use patterns and motives (Bonar et al., 
2017; Buckner et al., 2015; Hughes et al., 2014), social contexts of cannabis use (K. T. Phillips, 
Phillips, Lalonde, & Prince, 2018), cannabis use effects (e.g., working memory, anxiety 
symptoms, craving, and mood; (Buckner, Heimberg, & Schmidt, 2011; Buckner et al., 2015; 
Buckner, Zvolensky, et al., 2011; Rusby, Westling, Crowley, Mills, & Light, 2019; Schuster, 
Mermelstein, & Hedeker, 2016; Shrier, Walls, Kendall, & Blood, 2012; Testa, Wang, Derrick, 
Brown, & Collins, 2019). Among previous studies that have recorded cannabis use patterns, 
assessment weeks ranged from 2-16 weeks, and assessments spanned 3-5 times per day (Buckner 
et al., 2015; Hughes et al., 2014; K. T. Phillips et al., 2018). EMA compliance rates for cannabis 
use range from 70-90% (Buckner et al., 2015; Hughes et al., 2014; Preston et al., 2018; Shrier et 
al., 2012). These previous studies and design choices indicate that cannabis use pattern and 
health-related symptom data can be collected successfully via EMA.  
Two previous studies have measured cannabis use frequency, administration method use, 
and intoxication symptoms. In 2012, an EMA study was conducted among US adult daily/almost 
daily cannabis users (Hughes et al., 2014). The average participant age was 33 years (N = 142). 
Participants reported data with daily phone calls. Each morning for three months, participants 
reported their prior day’s cannabis use, intoxication symptoms, and other variables. Results 
indicated that cannabis was used on average 4 times per day, and cannabis use was higher on the 
weekends compared to weekdays. Most participants (59%) used more than 3 administration 
methods throughout the study, and 25% of participants used more than 2 administration methods 
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throughout the study. The most commonly reported administration method used was pipe/bong 
(49% of the total days), followed by blunts (33% of days), and joints (16% of days). The median 
intoxication on days when cannabis was used was 3.8 (of a 0 “did not get high” to 6 “got very 
high” scale). Intoxication scores were greater on the days when participants reported using blunts 
(4.3) compared to days when they reported joint or pipe (3.7) use (p < 0.001; Hughes et al., 
2014). These data highlight variability in cannabis use patterns as well as a relationship between 
cannabis administration method used and intoxication scores, but analyses did not examine their 
potential interaction.  
 In 2018, a study using EMA was conducted among a younger age group of cannabis 
users (15-24 years; N = 85) who reported using cannabis at least 2 times/week (Treloar 
Padovano & Miranda, 2018). Participants reported data using a palm pilot EMA device, and data 
collection occurred on a self-initiated basis as well as by random prompts for one week. Daily 
cannabis use frequency, administration method used, subjective intoxication symptom severity, 
and other related variables were assessed. Results indicated that average cannabis use time was 
in the afternoon. When tested with logistic multilevel models, cannabis use was significantly less 
likely to occur in the morning (OR = 0.10, ps < 0.001) and afternoon (OR = 0.29, ps < 0.001) 
compared to 12:00am-6:00am (referent group). There was no significant difference between 
cannabis use frequencies on the weekends compared to the weekdays. The most commonly 
reported administration method used was blunt (52.6%), followed by bowl (28.1%), bong 
(8.9%), joint (7.3%), and other (3.2%). As expected, intoxication symptoms significantly 
increased after cannabis use, compared to before cannabis use (Treloar Padovano & Miranda, 
2018). In sum, these studies provide information about daily and weekly cannabis use frequency, 
daily administration methods used, and changes in intoxication symptoms before and after 
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cannabis use. Missing from this work are measurements of respiratory symptoms. In addition, 
this foundation of EMA research with cannabis has not addressed the measurement of cannabis 
use frequency, administration methods use, and related intoxication and respiratory symptoms 
holistically as well as their interaction to better understand cannabis use patterns and risk for 
harm.  
Statement of the Problem 
 Cannabis is the most widely used illicit drug among young adults, and this group uses 
cannabis more than any other age group. Young adults are at a high risk for substance use and 
dependence including cannabis. Previous literature has revealed the weekly and daily variability 
of cannabis use frequency, but less is known regarding cannabis administration method use and 
cannabis-related intoxication and respiratory symptoms among young adult heavy cannabis 
users. The relationship between cannabis use frequency, administration method use, and 
cannabis intoxication and respiratory symptoms remains unclear. The current study aims to 
address these stated problems. The results from the proposed aims will inform cannabis 
intervention and education efforts and potential policy recommendations. 
The Present Study Aims and Hypotheses 
 This observational two-week clinical study will use EMA to collect real-time data on 
cannabis use frequency, cannabis administration method use, and cannabis-related intoxication 
and respiratory symptoms among young adult heavy cannabis users. There are two aims for the 
current study:  
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Aim 1. To characterize within week and day patterns of cannabis use frequency, number 
of administration methods used, and cannabis-related intoxication and respiratory symptoms 
among young adult heavy cannabis users.  
Hypothesis 1a. Consistent with previous data, frequency will vary significantly by day of 
week and time of day. We predict that cannabis use frequency will be lowest in the mornings and 
highest in the evenings. We estimate that cannabis use frequency will be higher on the weekends 
compared to the weekdays.  
Hypothesis 1b. Unique to this study, number of cannabis administration methods used 
will vary significantly by day of week and time of day. 
Hypothesis 1c. Unique to this study, self-reported intoxication and respiratory symptoms 
will vary significantly by day of week and time of day, such that intoxication and respiratory 
symptoms will be highest in the evenings and weekends and lowest in the mornings and on 
weekdays.  
Aim 2. To test the interaction of cannabis use frequency and cannabis administration 
method (combusted, other, and combination) use on cannabis-related intoxication and respiratory 
symptoms over a two-week period among young adult heavy cannabis users.  
Hypothesis 2a. Those who use other administration methods at high frequencies will have 
the highest intoxication symptoms relative to combusted and combination administration method 
sub-groups.  
Hypothesis 2b. Those who use combusted administration methods and at the highest 
frequencies will report the highest negative respiratory symptoms relative to other and 
combination administration method sub-groups.  
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Methods  
Participants 
 A total of 27 young adults who were aged 18-25 and lived in a US metropolitan area 
where recreational cannabis use was prohibited and CBD was legal were recruited for the current 
study. The sample size was informed by a power analysis for multi-level structured data (see 
Data Analysis).  
For inclusion criteria, participants were between 18-25 years of age (verified by 
identification card), reported using cannabis at least 5 days per week, had a cell phone that could 
receive text messages and open web links, and were willing to use their cell phone to receive text 
messages and complete online surveys for study procedures. Participants also tested positive for 
cannabis use via urinalysis at screening. Although cannabis can be detected in urine as far as 4 
weeks prior, this brief and rapid urinalysis test was the best way to confirm relatively recent 
cannabis use at screening.  
For exclusion criteria, participants must not have been diagnosed with a psychiatric 
disorder in the past six months (i.e., newly diagnosed or initiated treatment), which was assessed 
using self-report. This exclusion reduced risk for individuals whose psychiatric conditions may 
have been well-controlled but was inclusive of the young adult cannabis users who may have 
been likely to have psychiatric conditions (see Buckner et al., 2015). Previous similarly designed 
EMA studies of young adult cannabis users had not excluded for psychiatric conditions 
(unrelated to substance use disorders) with no evidence of adverse consequences (Buckner et al., 
2015; Hughes et al., 2014; K. T. Phillips et al., 2018; M. M. Phillips et al., 2014). In addition, 
participants who reported any medical condition/medication that could affect participant safety 
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or study outcomes were excluded (e.g., chronic obstructive pulmonary disease, asthma). 
Participants were excluded if they reported past month use of illicit drugs other than cannabis or 
had a positive urine drug screen (via Accutest MultiDrug Screen-5 Panel, Jant Pharmaceutical 
Corporation) for cocaine or opiates (unless participant self-reported prescription opioid use). 
Participants must not have been currently in treatment for illegal substance use (including 
cannabis or alcohol). Any participant who scored ≥ 27 on the NIDA-Modified ASSIST V2.0 
(National Institute on Drug Abuse, 2012) for heavy alcohol use were excluded (scores of 27 or 
greater indicate a high risk patient). Participants could not be pregnant (tested via urinalysis at 
screening), intend to become pregnant, or were breastfeeding during the study. Participants who 
reported being cannabis users but indicated that they used primarily CBD were excluded from 
the study. Of note is that tobacco use was neither an inclusion or exclusion criteria and was 
allowed to vary freely among included participants. This choice was more inclusive of the 
cannabis user population based on preliminary data collected among this same population (>50% 
were tobacco co-users; see Rudy, 2018) and challenges in defining cannabis-only use when 
cannabis administration methods often involve tobacco consumption (e.g., blunts). Participants 
were recruited by IRB-approved advertisements through existing research registries and by word 
of mouth. 
Procedures 
 Potentially eligible participants underwent a two-part screening process. Recruitment 
information directed potential participants to complete an online or phone-based screening 
survey, which evaluated their demographics, health, cannabis and other substance use for initial 
eligibility screening. Individuals who appeared to meet eligibility criteria from this pre-screening 
were invited to schedule an in-person appointment at the clinical laboratory. At the in-person 
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screening, informed consent was obtained followed by verification of eligibility status and 
familiarization with study procedures. During appointment scheduling, participants were 
reminded to bring their identification card (passport or state license) for age verification and to 
not arrive under the influence or intoxicated (from cannabis or any other illicit substance) to the 
appointment. During informed consent, all study procedures and potential risks/benefits were 
fully described to participants, and they were told they were able to withdraw from the study at 
any time without any penalty by contacting the study coordinator (via phone, email or text). 
Participants were not required to sign their informed consent form but indicated agreement 
verbally to the research assistant (to protect their identity). Once consented, participants 
completed a set of baseline questionnaires, similar to the phone screening questions. Urinalysis 
was completed to verify eligibility (pregnancy and drug use status). At this time, participants 
were measured for their height and weight, and their expired air carbon monoxide was measured 
(used to assess recent smoke exposure via cannabis and/or tobacco use). To increase participant 
privacy, participants completed a separate survey, which asked questions about contact 
information and payment preferences. Following eligibility verification, enrolled participants 
practiced the data collection procedures (daily text messages). This training involved practice 
using the text messaging system with the participant’s own cell phone and asking questions 
about any study procedures. At the end of the in-person assessment, eligible participants were 
given a written list of the daily questions and a study identification card, which had the 
participant’s unique identification number, the research laboratory’s phone number, and the date 
range of the data collection period (two weeks).  
On the first Monday after their in-person assessment, eligible participants began the two-
week data collection period (see K. T. Phillips et al., 2018; M. M. Phillips et al., 2014) for details 
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regarding the feasibility of a two-week data collection period). In response to three random text 
messages to their cell phone each day, participants reported daily cannabis use (number of “hits” 
taken for each administration method since last assessment) and self-reported current cannabis 
intoxication and respiratory symptoms (see Daily Measures). An adaptive random-interval text 
message schedule was created for each participant based on their individual sleep-wake cycle, 
which was assessed at the in-person assessment (Mehl & Conner, 2012). Participants were 
randomly assessed in the morning (reported waking time to 12:00pm), afternoon (12:00pm to 
5:59pm), and evening (6:00pm to reported sleep time). For example, if a participant woke up at 
9:00am, they were texted at a random time between 9:00am and 12:00pm, and if the participant 
went to bed at 10:00pm, they were texted randomly between 6:00pm and 10:00pm. Participants 
were not texted while they were assumed to be sleeping. Text messages containing a web-link to 
the daily questions were used to collect daily data. Participants were instructed to complete the 
survey as soon as they received the text message. If participants did not complete the 
questionnaire, it was counted as a missed assessment. Participants were sent a reminder text 10 
minutes after the first text in each time block (i.e., morning, afternoon, and evening) was sent. 
The first text message within each time block were not sent within one hour of each other. 
Participants earned $10 for completion of the baseline assessment, $1/completed daily 
assessment ($3/day), and participants who completed 90% or more of the daily assessments 
received a $50 bonus following the completion of data collection. Participants could earn up to 
$102 ($10+$42+$50 bonus). After the final day of data collection, participants were paid via 
cash in person or emailed Amazon gift card. To increase participant compliance, every 
Wednesday and Friday throughout the two weeks, participants were notified via text of their 
response rate percentage and how much payment they had earned (Mehl & Conner, 2012). 
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Compliance was also maximized by providing participants with letters for employers/professors 
to help avoid negative consequences associated with participation.  
Measures 
Baseline measures. The study-applicable measures completed at the in-person screening 
assessment included demographics, cell phone eligibility questions, daily sleep-wake cycle, 
psychiatric and health questions, respiratory symptoms, and tobacco/cannabis/other substance 
use history. Several other measures were completed in the baseline survey that will not be 
described here because these measures are not considered primary measures of the current study. 
Other measures included depression symptoms, stress symptoms, pain symptoms, cannabis 
dependence, marijuana motives, and marijuana effect expectancy.  
Demographic measures included gender, age, race/ethnicity, level of school attainment, 
employment status, income level, and pregnancy/breastfeeding status. Gender was assessed by 
asking “Which of the following best describes your gender? [Note: cisgender means identifying 
with the sex assigned to you at birth, while transgender means not identifying with the sex 
assigned to you at birth]” Answer options included “Cisgender man,” “Cisgender woman,” 
“Transgender man,” “Transgender woman,” “Non-binary/ Gender non-conforming,” “Agender,” 
and “Other” which included a text box for participants to write their response. Age was assessed 
by asking “How old are you?” There was a dropdown answer option to input age in years. 
Race/ethnicity was assessed by asking “How would you describe your racial or ethnic 
background?” Answer categories included “White or European-American,” “Black, Afro-
Caribbean, or African American,” “Asian American,” “American Indian or Alaska Native,” 
“Native Hawaiian or Other Pacific Islander,” “Middle Eastern or Arab American,” “Multiracial,” 
or “Other” which included a text box for participants to write their response (Youth Risk 
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Behavior Survey Questionnaire, 2015). Participants were asked “Do you consider yourself 
Hispanic/Latinx?” with response options “Yes” and “No.” School level was determined by 
asking “What is the highest level of school you have completed or the highest degree you have 
received?” Answer options included the following categories: “high school graduate,” “GED or 
equivalent,” “some college/no degree,” “associate degree,” “bachelor’s degree,” “master’s 
degree,” and “professional or doctoral degree” (National Institute on Drug Abuse Clincal Trials 
Network, 2015). Employment status was determined by asking “Which of these best describes 
your current employment status?” Answer options included “Working now, full-time,” “Working 
now, part-time,” “Only temporarily laid off, sick leave, or maternity leave,” “Looking for work, 
unemployed,” “Retired,” “Non-working disabled, permanently or temporarily,” “Keeping 
house,” “Military,” “Non-working student,” and “Don’t know” (University of Michigan, 2007). 
Due to few responses in each category, results for employment status were collapsed into three 
categories: “student,” “working,” and “Non-working.” Household income was assessed by 
asking “Which of the following income categories best describes your total household income, 
before taxes, last year?” Answer options included “Less than $10,000,” “$10,000 to $19,999,” 
“$20,000 to $29,999,” “$30,000 to $39,999,” “$40,000 to $49,999,” “$50,000 to $59,999,” 
“$60,000 to $69,999,” “$70,000 to $79,999,” “$80,000 to $89,999,” “$90,000 to $99,999,” and 
“$100,000 or more” (Pew Research Center, 2015). Pregnancy was assessed (in addition to the 
urine screening) by asking “Are you pregnant, breastfeeding, or intend to become pregnant in the 
next three weeks?” Answer options included “Yes” and “No.”  
Several questions were asked about participants’ willingness to use their personal cell 
phone for study procedures. Three questions were asked: “Do you have a cell phone with an 
active texting plan?,” “Do you have a cell phone that has the ability to open web links?,” and 
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“Are you willing to receive text messages and complete online surveys on your cell phone for 
study purposes?” Answer options included “Yes” and “No.” 
Daily sleep-wake cycle was assessed using questions from the Pittsburgh Sleep Quality 
Index (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). Participants were asked: “During the 
past month, what time have you usually gone to bed at night?” “During the past month, what 
time have you usually gotten up in the morning?” and “During the past month, how many hours 
of actual sleep did you get at night? (This may be different than the number of hours you spent in 
bed.)” Participants were given a blank box to insert their answer. Results were used to determine 
when daily text messages would be delivered to participants. 
Perceived health was assessed by asking “Would you say that in general your health is… 
excellent, very good, good, fair, or poor?” (National Center for Chronic Disease Prevention and 
Health Promotion, 2018). Due to few responses in each category, results for perceived health 
were collapsed into three categories: “excellent/very good,” “good/fair,” and “poor.” Psychiatric 
and other health conditions were assessed by asking “Do you have a recent (in the past six 
months) diagnosis from a doctor, nurse, or other healthcare provider for any psychiatric 
conditions like depression or anxiety?” and “Do you have a recent or current diagnosis from a 
doctor, nurse, or other healthcare provider for any health conditions like high/low blood pressure 
or asthma?” Answer options included “Yes” and “No.” Individuals who responded “Yes” were 
probed for further detail to determine current diagnosis/treatment status to determine eligibility. 
Medications were assessed by asking “List all medicines that you are currently taking (include 
medicines as described drugs, over-the-counter drugs, vitamins, and inhalers). Name of drug. 
Strength. Frequency taken. Date started.” Participants were given a blank box to insert their 
answer. 
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Respiratory symptoms at baseline were assessed with the Clinical COPD Questionnaire 
(CCQ, van der Molen et al., 2003). The CCQ includes ten questions total. Six questions assess 
how often one experiences shortness of breath while at rest and during physical activity, concern 
about getting a cold, depressive symptoms due to breathing problems, time spent coughing, and 
time producing sputum (i.e., phlegm or mucus). Answers options for the first six questions 
included: “never” (0), “hardly ever” (1), “a few times” (2), “several times” (3), “many times” (4), 
“a great many times” (5), and “almost all the time” (6). The final four questions assessed 
perceived limitations in strenuous and moderate physical activity and perceived limitations in 
daily and social activities due to breathing problems. Answer options for the final four questions 
included: “not limited at all” (0), “very slightly limited” (1), “slightly limited” (2), “moderately 
limited” (3), “very limited” (4), “extremely limited” (5), and “totally limited, or unable to do” 
(6). Items were totaled for a composite score ranging from 0-60 with zero indicating low/non-
severe respiratory symptoms and 60 indicating high/severe respiratory symptoms.  
The NIDA Modified ASSIST V2.0 (NIDA, 2012) was used to identify degree of 
dependence on cannabis, alcohol, tobacco, and other drugs. The NIDA Modified ASSIST V2.0 
was altered for the current study by adding heavy alcohol use as one of the drugs listed in the 
questions. Lifetime substance use was assessed with the question “In your LIFETIME, which of 
the following substances have you ever used? * For prescription medications, please report using 
these substances in any way a doctor did not direct you to use them, including: using it without a 
prescription of your own, using it in greater amounts, more often, or longer than you were told to 
take it, or using it in any other way a doctor did not direct you to use it.” Participants responded 
“Yes” or “No” for each of the following substances: “Cannabis (marijuana, pot, grass, hash, 
etc.),” “Cocaine (coke, crack, etc.),” “Prescription stimulants (Ritalin, Concerta, Dexedrine, 
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Adderall, diet pills, etc.),” “Methamphetamine (speed, crystal meth, ice, etc.),” “Inhalants 
(nitrous oxide, glue, gas, paint thinner, etc.),” “Sedatives or sleeping pills (Valium, Serepax, 
Ativan, Xanax, Librium, Rohypnal, GHB, etc.),” “Hallucinogens (LSD, acid, mushrooms, PCP, 
Special K, ecstasy, etc.),” “Street opioids (heroin, opium, etc.),” “Prescription opioids (fentanyl, 
oxycodone [OxyContin, Percocet], Hydrocodone [Vicodin], methadone, buprenorphine, etc.),” 
“Heavy alcohol use (more than 4 drinks per day),” and “Other – specify: ______.” The next four 
questions assessed use frequency of, strong desires and urges to use, frequency of health, social, 
legal, or financial problems due to, and failure to complete normal expectations due to the listed 
substances in the past three months with answer options including “never” (0), “once or twice” 
(5), “monthly” (6), “weekly” (7), and “daily or almost daily” (8). The next three questions 
assessed friend or relative concerns about substance use, cessation and reduction attempts, and 
injection of substances. Answer options for the final three questions included: “no, never” (0), 
“yes, but not in the past 3 months” (3), and “yes, in the past 3 months” (6). Items were summed 
to create a composite score. Low risk composite scores are 0-3, moderate risk scores are 4-26, 
and high risk scores at 27 or greater.  
The next several questions assessed past month illicit drug use and treatment. The first 
question in this section prompted, “Have you used any illegal drugs excluding cannabis in the 
past 30 days?” and the second question prompted, “Have you ever received treatment or 
counseling for your use of alcohol or any drug not counting cigarettes?” Answer options 
included “Yes” and “No.” 
Tobacco use history was assessed, and questions included lifetime and current use status 
of cigarettes, electronic cigarettes, cigars, cigarillos, little cigars, hookah, tobacco pipe, and 
smokeless tobacco products (dip, snuff, and snus). Instructions clearly stated that these questions 
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refer to tobacco use alone and not in combination with cannabis or THC-containing 
material/liquid. Lifetime tobacco product use was assessed by asking “Which, if any, of the 
following tobacco or nicotine products have you ever used or tried? Please select all that apply” 
(Ganz et al., 2018; Lariscy et al., 2013; Niaura et al., 2019; Rath, Villanti, Abrams, & Vallone, 
2012). Past 30-day tobacco product use was determined (for lifetime use products) by asking 
“During the last 30 days, on how many days have you used any of the following tobacco 
products? (For cigarettes, cigars, cigarillos, e-cigarettes, and hookah/shisha, "even 1 puff").” 
Available answer options for lifetime and past 30-day tobacco use included “Cigarettes,” 
“Traditional cigars (Macanudo, Romeo y Julieta, or Arturo Fuente),” “Pipe (with tobacco),” 
“Little cigars/cigarillos (like Black & Milds, Swisher Sweets, or Phillies Blunt),” “Electronic 
cigarettes or E-cigarettes (like Blu, Logic, or NJOY),” “Chewing tobacco (like Levi Garrett, Red 
Man, or Beech Nut),” “Dip/snuff (like Skoal or Copenhagen),” “Snus (like Camel Snus),” 
“Dissolvable tobacco products (like Ariva, Stonewall, Camel Orbs, Sticks or Strips),” and 
“Hookah/shisha (hookah tobacco).” 
Cannabis use history and intensity was assessed using the Daily Sessions, Frequency, 
Age of Onset, and Quantity of Cannabis Use (DFAQ-CU) Inventory (Cuttler & Spradlin, 2017).  
The DFAQ-CU was developed to accurately assess self-reported cannabis use frequency, amount 
of cannabis used, and age of cannabis use onset. Unique to the DFAQ-CU, no previous 
psychometrically tested cannabis use inventory has measured a wide variety of cannabis 
administration methods, amount of personal cannabis use, and THC levels of the cannabis used 
(Cuttler & Spradlin, 2017). It was critical to assess these cannabis use characteristics for the 
current study in order to understand baseline participant attributes. Lifetime cannabis use was 
assessed by the question “Have you ever used cannabis?” with response options of “No” and 
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“Yes.” To assess last session of cannabis use, the following question was asked, “Which of the 
following best captures when you last used cannabis?” Response options included “over a year 
ago,” “9-12 months ago,” “6-9 months ago,” “3-6 months ago,” “1-3 months ago,” “less than 1 
month ago,” “last week,” “this week,” “yesterday,” “today.” In the original inventory, the answer 
option “I am currently high” was included for the previous question, and two additional 
questions appear in the original inventory: “How mentally high are you right now?” and “How 
physically high are you right now?” This answer option and two following questions were 
removed for the current study. Participants were told not to come to the laboratory under the 
influence of any illegal substances and were verbally asked prior to completing consent if they 
had followed these study directions.  
Frequency of cannabis use was characterized by asking 10 items, which are listed below:  
(1) “Which of the following best captures the average frequency you currently use 
cannabis?” Answer options included “I do not use cannabis,” “less than once a year,” “once a 
year,” “once every 3-6 months (2-4 times/yr),” “once every 2 months (6 times/yr),” “once a 
month (12 times/yr),” “2-3 times a month,” “once a week,” “twice a week,” “3-4 times a week,” 
“5-6 times a week,” “once a day,” and “more than once a day.”;  
(2) “Which of the following best captures how long you have been using cannabis at this 
frequency?” Answer options included “less than 1 month,” “1-3 months,” “3-6 months,” “6-9 
months,” “9-12 months,” “1-2 years,” “2-3 years,” “3-5 years,” “5-10 years,” “10-15 years,” “15-
20 years,” and “more than 20 years.”;  
(3) “Before the period of the time you indicated above, how frequently did you use 
cannabis?” Answer options included “I did not use cannabis,” “less than once a year,” “once a 
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year,” “once every 3-6 months (2-4 times/yr),” “once every 2 months (6 times/yr),” “once a 
month (12 times/yr),” “2-3 times a month,” “once a week,” “twice a week,” “3-4 times a week,” 
“5-6 times a week,” “once a day,” and “more than once a day.”;  
(4) “How many days of the past week did you use cannabis?” Answer options included 
“0 days,” “1 day,” “2 days,” “3 days,” “4 days,” “5 days,” “6 days,” and “7 days.”;  
(5) “Approximately how many days of the past month did you use cannabis?” There was 
a blank space to indicate how many days.  
(6) “Which of the following best captures the number of times you have used cannabis in 
your entire life?” Answer options included “1-5 times in my life,” “6-10 times in my life,” “11-
50 times in my life,” “51-100 times in my life,” “101-500 times in my life,” “501-1000 times in 
my life,” “1001-2000 times in my life,” “2001-5000 times in my life,” “5001-10,000 times in my 
life,” and “more than 10,000 times in my life.”; 
(7) “Which of the following best captures your pattern of cannabis use throughout the 
week?” Answer options included “I do not use cannabis at all,” “I only use cannabis on 
weekends,” “I only use cannabis on weekdays,” and “I use cannabis on weekends and 
weekdays.”; 
(8) “How many hours after waking up do you typically first use cannabis?” Answer 
options included “I do not use cannabis at all,” “12-18 hours after waking up,” “9-12 hours after 
waking up,” “6-9 hours after waking up,” “3-6 hours after waking up,” “1-3 hours after waking 
up,” “within 1 hour of waking up,” “within ½ hour of waking up,” and “immediately upon 
waking up.”; 
(9) “How many times a day, on a typical weekday, do you use cannabis?” There was a 
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blank space to indicate how many times; and  
(10) “How many times a day, on a typical weekend, do you use cannabis?” There was a 
blank space to indicate how many times.  
Cannabis administration method was assessed by asking 6 items: 
(1) “What is the primary method you use to ingest cannabis?” Modified answer options 
included “I do not use cannabis,” “joint or spliff,” “blunt (cigar sized joints),” “bowl or hand 
pipe that does not include water,” “bong (water pipe),” “dab,” “vaporizer (e.g., Volcano, vape 
pen),” and “edibles (brownies, teas, tinctures, sprays).”;  
(2) “Which of the following other methods to ingest cannabis do you use regularly (at 
least 25% of the time you use cannabis)? [Mark all that apply]” Modified answer options 
included “I do not use cannabis,” “joint or spliff,” “blunt (cigar sized joints),” “bowl or hand 
pipe that does not include water,” “bong (water pipe),” “dab,” “vaporizer (e.g., Volcano, vape 
pen),” and “edibles (brownies, teas, tinctures, sprays).”; 
(3) “Which of the following methods to ingest cannabis have you used in your lifetime?” 
Modified answer options included “I do not use cannabis,” “joint or spliff,” “blunt (cigar sized 
joints),” “bowl or hand pipe that does not include water,” “bong (water pipe),” “dab,” “vaporizer 
(e.g., Volcano, vape pen),” and “edibles (brownies, teas, tinctures, sprays).”; 
 (4) “What kinds of cannabis vaporizers do you use regularly (at least 25% of the time that 
you use cannabis)? [Mark all that apply]” Answer options included “Vaporizer for dried 
cannabis,” “Vaporizer for cannabis concentrates such as wax or shatter,” and “Vaporizer for 
oils/liquids containing cannabis.”  
(5) “What is the primary form of cannabis you use?” Modified answer options included 
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“None,” “Marijuana (dried, bud, flower),” “Concentrates (e.g., oil, wax, shatter, butane hash oil, 
dabs),” “Edibles,” and “Other.” The answer option “Other” will have a blank space.; and 
(6) “What other forms of cannabis do you use regularly (at least 25% of the time you use 
cannabis)? [Mark all that apply]” Answer options included “None,” “Marijuana (dried, bud, 
flower),” “Concentrates (e.g., oil, wax, shatter, butane hash oil, dabs),” “Edibles,” and “Other.” 
The answer option “Other” will have a blank space.  
To assess the amount of cannabis that participants use, a picture was shown of cannabis 
(see Figure 3) to assist participants in their estimation. The instructions indicated, “Please use the 
image below to refer to various quantities of marijuana. The image is not to scale; the dollar bill 
is included to help provide size perspective… Clearly indicate the number of grams of marijuana 
you use with a number between 1 – 100. Do NOT include other forms of cannabis you may use 
(such as concentrates). You may use up to 3 decimals to indicate amounts under 1 gram. Note: 
1/8 of a gram = 0.125 grams, ¼ of a gram = 0.25 grams, ½ of a gram = 0.5 grams, ¾ of a gram = 
0.75 grams. 1/8 of a ounce = 3.5 grams, ¼ of an ounce = 7 grams, ½ ounce = 14 grams, 1 ounce 
= 28 grams.” Participants used the image to answer the following 3 items that comprise cannabis 
use amount:   
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Figure 3. DFAQ-CU inventory image. Image from the DFAQ-CU Inventory for participants to 
estimate their amount of cannabis use.   
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(1) “In a typical session, how much marijuana do you personally use?”; 
(2)  “On a typical day you use marijuana, how much do you personally use?”; and 
(3) “In a typical week you use marijuana, how much marijuana do you personally use?”  
 To further assess amount of cannabis used and estimated strength of cannabis used, 
participants answered the following 8 items:  
(1) “On a typical day you use marijuana, how many sessions do you have?” A blank 
space was provided to indicate number of sessions.;  
(2) “What is the average THC content of the marijuana you typically use? Leave blank if 
you do not know.” Answer options included “0-4%,” “5-9%,” “10-14%,” “15-19%,” “20-24%,” 
“25-30%,” and “greater than 30%.”;  
(3) “In a typical session you use cannabis concentrates, how many hits do you personally 
take?” A blank space was provided to indicate number of hits.; 
(4) “On a typical day you use cannabis concentrates, how many hits do you personally 
take?” A blank space was provided to indicate number of hits.; 
(5) “How many hits of cannabis concentrates did you personally take yesterday?” A 
blank space was provided to indicate number of hits.; 
(6) “On a typical day you use cannabis concentrates, how many sessions do you have?” A 
blank space was provided to indicate number of sessions.;  
(7) “What is the average THC of the concentrates you typically use? Leave blank if you 
do not know.” Answer options included “0-9%,” “10-19%,” “20-29%,” “30-39%,” “40-49%,” 
“50-59%,” “60-69%,” “70-79%,” “80-89%,” and “greater than 90%.”; and 
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(8)  “When you eat edibles, how many milligrams of THC do you personally ingest in a 
typical session?” A blank space was provided to indicate milligrams of THC.  
The following eight questions assessed lifetime cannabis use attributes: 
(1) “What is your current age?” A blank space was provided to indicate age.; 
(2) “How many years in total have you used cannabis?” A blank space was provided to 
indicate years.; 
(3) “How old were you when you FIRST tried cannabis?” A blank space was provided to 
indicate age.; 
(4) “Has there ever been a time in your life when you used cannabis regularly (2 or more 
times/months)?” Answer options included “yes” or “no.”; 
(5) “How old were you when you FIRST STARTED using cannabis regularly (2 or more 
times/month)?” A blank space was provided to indicate age.; 
(6) “Has there been any time in your life when you used cannabis on a daily or nearly 
daily basis for 6 months or longer?” Answer options were “yes” and “no.”; 
(7) “How old were you when you FIRST STARTED using cannabis on a daily or nearly 
daily basis?” A blank space was provided to indicate age.; and 
(8) “Which of the following best captures the average frequency that you used cannabis 
before the age of 16?” Answer options included “more than once a day,” “once a day,” “5-6 
times a week,” “3-4 times a week,” “twice a week,” “once a week,” “2-3 times a month,” “once a 
month,” “once every 2 months (6 times/yr.),” “once every 3-6 months (2-4 times/yr.),” “once a 
year,” “less than once a year,” and “never.” 
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 The final three items of this measure assessed medicinal cannabis use: 
(1) “Do you have a physician’s recommendation to use cannabis for medicinal 
purposes?” Answer options included “no,” “yes,” and “yes, but I use it for both medicinal and 
recreational purposes.”; 
(2) “Which medical conditions do you use cannabis for?” A blank space was provided for 
completing answer.; and 
(3) “What percentage of the time do you use cannabis for recreational (rather than 
medicinal) purposes?” A blank space was provided for estimating percentage of time.  
The DFAQ-CU is scored based on the 6 factors (daily sessions, frequency, age of onset, 
marijuana quantity, concentrate quantity, and edibles quantity). Each of the items associated with 
each factor were standardized (z-transformed) to calculate means (Cuttler & Spradlin, 2017). 
Finally, one question on the baseline measure assessed CBD use. Instructional text 
indicated, “THC and CBD are naturally occurring substances found in cannabis plants. Some 
cannabis plants/products contain only CBD; some cannabis plants/products contain only THC; 
and other cannabis plants/products contain a combination of both CBD and THC” (World Health 
Organization, 2018). Participants answered the question “Most of the time that you use a 
cannabis product, do you use a product that contains...” Answer options included, “all CBD,” 
“mostly CBD and some THC,” “a combination of CBD and THC,” “mostly THC and some 
CBD,” “all THC,” and “I don’t know.” 
Daily Measures. Daily assessments were collected using online survey links embedded 
into automated text messages sent to participants’ cell phones. Daily measures included items 
that assessed cannabis use frequency, cannabis administration methods, and subjective cannabis 
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intoxication and respiratory symptoms. The first question asked for the participant’s unique 
study identification number (assigned at the screening appointment). During each assessment, 
participants were asked “Since the last assessment, have you used cannabis?” Participants 
responded “Yes” or “No”. The next question asked “How many hours ago did you last use 
cannabis?” Participants input a number indicating how many hours, and “1” hour indicated one 
hour ago or less. All measures were developed and/or adapted for this study based on previous 
work. Psychometric data where available has been included below.  
Participants who indicated recent cannabis use were then asked what method(s) of 
administration they had used since the last assessment with eight questions with the same stem. 
“Since the last call, have you used…”: “a joint,” “a blunt,” “a bowl/pipe,” “a bong, “a 
vaporizer,” “a dab,” and “an edible” (Modified from Rudy et al., 2018). Answer options for each 
administration method were “Yes” and “No.” For each administration method that a participant 
used since the last assessment, participants completed an additional question regarding “hits” of 
use: “Since the last assessment, how many hits from a... ‘joint,’ ‘blunt,’ ‘bowl/pipe,’ ‘bong,’ 
‘vaporizer,’ or ‘dab/rig’... did you have?” (Shrier et al., 2012). Edibles cannot be quantified in 
hits; therefore, edibles were assessed differently, “Since the last assessment, how many edibles 
did you consume?” Participants reported a number in a blank space provided. At each 
assessment, participants’ use of cannabis administration methods were used to categorize them 
as either combusted-only (joint, blunt, bowl/pipe, bong), other-only (vaporizer, dab, edible), and 
combination (use of any combusted method and other method since the last assessment). This 
level of categorization at each assessment (i.e., morning, afternoon evening) was used for Aim 1 
analysis. Participants were also categorized in terms of their cannabis administration method use 
across the two-week data collection period taking into account the total number of assessments 
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available and using the same three levels (combusted, other-only, and combination) for Aim 2 
analysis. No specific psychometric data is available for this measure.  
To assess intoxication, participants were prompted to indicate their subjective 
intoxication level on a 5-point scale of 0 (not at all) to 4 (extremely) with two questions “How 
mentally stoned do you feel right now?” and “How physically stoned do you feel right now?” 
(Bidwell et al., 2018). Responses to these two intoxication items were summed to create a 
composite score of intoxication for each assessment (possible scores ranged from 0-8, Aim 1); 
these sum scores were averaged across the two-week period for Aim 2 analyses. Cronbach’s 
alpha for the two subjective intoxication items was 0.72, indicating good internal consistency.   
Cannabis-related respiratory symptoms were assessed using three questions adapted from 
EMA studies among individuals with respiratory conditions (Everhart, Smyth, Santuzzi, & Fiese, 
2010; Nazarian, Smyth, & Sliwinski, 2006) rated on a seven-point Likert scale (0=not at all, 
6=extremely): “Since the last assessment, how bad was your coughing and wheezing?”, “Since 
the last assessment, how bad was your throat irritation?”, and “Since the last assessment, how 
bad was your phlegm or chest mucus?” (Everhart et al., 2010; Nazarian et al., 2006). Cronbach’s 
alpha for the three subjective respiratory symptoms was 0.82, indicating high internal 
consistency. Responses to these three respiratory items were summed to create a composite 
respiratory symptom score for each assessment (Aim 1); these sum scores were averaged across 
the two-week period for Aim 2 analysis.  
Finally, there was one additional question at the end of the final text sent to participants. 
The Marijuana Ladder is a type of visual analog scale with 10 “rungs” on the ladder and 10 
corresponding statements that describe states of cannabis use change (Slavet et al., 2006). The 
statements range from “I enjoy using marijuana and have decided never to change it. I have no 
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interest in changing the way I use marijuana” to “I have changed my marijuana use and will 
never go back to the way I used marijuana before.” With foundations in the Transtheoretical 
Model, the statements correspond to the five states of change: pre-contemplation, contemplation, 
preparation, action, and maintenance (Prochaska & Velicer, 1997). Participants were given 
instructions that stated “Each rung of this ladder shows where a person might be in thinking 
about changing their marijuana use. Select the number that best matches where you are now.” 
Scores ranged from 1 to 10, with 1 indicating no intentions to change and 10 indicating that the 
person is in the maintenance phase. 
In total, participants were asked to complete a maximum of 21 items for each daily 
assessment and a maximum of 22 items for the final assessment.  
Data Analysis 
Power Analysis. Power analysis for multilevel models are complex, in that accurate 
parameter estimates are needed for all estimated model parameters. For this study, the primary 
outcomes were cannabis use frequency, cannabis administration method use, and cannabis-
related intoxication and respiratory symptoms, and there were no previous studies that examined 
these outcomes in the same manner in which we did. Fortunately, previous studies have provided 
estimates of the frequency of cannabis use expected per day (Hughes et al., 2014; Walden & 
Earleywine, 2008). We used these estimates to generate a sample dataset to conduct a power 
analysis for cannabis use frequency and estimated the sample size needed to detect a difference 
by day of week and time of day (Aim 1). Using the following equation, = 𝛔𝐭𝐨𝐭
𝟐 (𝟏 +
(𝐧 − 𝟏)𝛒)
(𝐳𝛂/𝟐 + 𝐳𝛃)
𝟐 
𝐧∆𝟐
, 𝐩 =
𝛔𝐛
𝟐
𝛔𝐭𝐨𝐭
𝟐  , where m is the number of participants, 𝛔𝐭𝐨𝐭
𝟐  is the total variance, 
n is the number of observations per participant, 𝛔𝐛
𝟐 is the between subjects’ variance, 𝐳𝛂/𝟐 is the 
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alpha level z-score,  𝐳𝛃 is the beta level z-score, and Δ is the expected change in frequency. To 
detect a difference in daily cannabis use frequency with a power ranging from 0.80 to 0.90 and 
α=.05, the number of subjects needed ranged from 41 to 55. We anticipated 70-90% compliance 
based on previous studies, which measured cannabis use and alcohol use using EMA (Collins et 
al., 2003; Hughes et al., 2014; Hughes, Naud, Budney, Fingar, & Callas, 2016). Anticipating 
conservative retention and enrollment rates, we aimed to recruit 65 participants. We also 
examined sample sizes used in similarly designed recent studies using EMA to measure cannabis 
use and alcohol use (assessments 3 times/day for 14 days) and found sample sizes ranging from 
50-60 (Cohn, Hagman, Moore, Mitchell, & Ehlke, 2014; K. T. Phillips, Phillips, Lalonde, & 
Tormohlen, 2015). When data collection ended, we had consented 40 participants, and 27 of 
those participants were eligible (indicating that we collected 65.9% of the intended sample).  
Dataset Preparation. After data collection was completed, the data was checked for 
missing data and other data irregularities. Regarding missing data, of the 27 eligible participants, 
18 (69.0%) completed 90% (38/42 surveys) or more of the total daily surveys. All 27 (100%) 
participants completed 69% (29/42 surveys) of the total daily surveys. Of the total number of 
daily surveys administered to all participants (N=1134), 92 surveys were missing (8.1%). The 
number of missing surveys during week 1 was 41 (of the total 567 week 1 surveys; 7.2%), and 
the number of missing surveys during week 2 was 51 (of the total 567 week 2 surveys; 9.0%). 
The number of missing morning daily surveys was 49 (of 378 total morning surveys; 13.0%). 
The number of missing afternoon daily surveys was 18 (of 378 total afternoon surveys; 4.8%), 
and the number of missing evening daily surveys was 25 (of 378 total evening surveys; 6.6%). 
The number of missing daily surveys by day of the week was fairly even across days ranging 
from 5.6% missing on Wednesdays to 12.3% missing on Thursdays. There were 14 daily surveys 
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(of 1134 total daily surveys; 0.01%) that had at least one missing answer for either of the daily 
intoxication symptom questions. A conservative approach was taken with the summed 
intoxication symptom scores, such that if there was a missing answer for one or both of the 
intoxication symptom questions at each time point, that time point counted as missing. Finally, 
there were 23 daily surveys (of 1134 total daily surveys; 0.02%) that had at least one missing 
answer for any of the daily respiratory symptom questions. A conservative approach was taken 
with summed respiratory symptom scores, such that if there was a missing answer for one or 
more of the respiratory symptom questions at each time point, that time point counted as 
missing. In sum, the missingness observed in the study was relatively low compared to other 
studies with similar designs. Of note, several other similarly designed EMA studies did not 
utilize any imputation techniques (Bonar et al., 2017; Buckner et al., 2015; Hughes et al., 2014; 
Shrier et al., 2012). Finally, the planned statistical techniques for which missing data is relevant 
(i.e., linear mixed models) can handle missing data in the models. Thus, given the distribution of 
missing data for the current study, the use of previous literature to guide decision-making, and 
the ability for our planned statistical techniques to handle missing data, no imputation techniques 
were used for any analyses in this study. There were no other data irregularities to report among 
the dataset as a whole.  
Following data cleaning/preparation, the sample was characterized by demographics, 
cannabis use behaviors and history using the DFAQ-CU (Cuttler & Spradlin, 2017), and tobacco 
use behaviors (Ganz et al., 2018; Lariscy et al., 2013; Niaura et al., 2019; Rath et al., 2012). A 
summed score was created and reported for baseline respiratory symptoms using the CCQ (van 
der Molen et al., 2003). Enrolled and excluded participants were compared on baseline 
characteristics using bivariate tests.  
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Aim 1 Data Preparation and Analysis.  
Assumptions for the linear mixed models utilized here included the use of continuous 
dependent variables, a within-subjects factor with at least two groups (i.e., time points), a 
between-subjects factors with at least two independent groups, a linear relationship between 
variables, homogeneity of variance, and the residuals with a normal distribution. All assumptions 
were met for the linear mixed models except for residual normality. All of the main outcome 
variables for Aim 1 (cannabis use frequency, number of cannabis administration methods used, 
intoxication symptoms, and respiratory symptoms) were positively skewed; therefore, we opted 
to use a square root transformation for each dependent variable. Square root transformed 
dependent variables were the best model fit compared to log transformations or untransformed 
variables. The final analytical sample for Aim 1 was 27.  
Following data cleaning, linear mixed models were conducted to characterize within 
week and day patterns of cannabis use frequency, number of administration methods used, and 
cannabis-related intoxication and respiratory symptoms. Dependent measures for this analysis 
were 1) cannabis use frequency (i.e., sum of cannabis hits across methods at each assessment ~ 3 
time points per day; model 1), 2) number of cannabis administration methods used (i.e., sum of 
methods with >0 hits endorsed at each assessment ~ 3 time points per day; model 2), cannabis-
related intoxication symptoms (i.e., sum score of intoxication items at each assessment ~ 3 time 
points per day; model 3), and cannabis-related respiratory symptoms (i.e., sum score of 
respiratory items at each assessment ~ 3 time points per day; model 4). Repeated measures were 
treated as fixed factors to examine the time course of these dependent measures: 1) assessment 
time of day [morning, afternoon, evening], 2) day of week [1-7], and 3) week [1, 2]). A subject-
level random factor (i.e., participant) was included to maximize model fit for each of our 
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dependent outcomes (assessed using information criteria provided; e.g., -2 Log likelihood 
values). Interactions were examined including week by day of week, week by time of day, day of 
week by time of day, and week by day of week by time of day. The interaction of week by day of 
week was the only interaction term that contributed to the models and was subsequently included 
in all four models. After choosing the best fitting model, we explored mean differences among 
measures with significant effects of fixed factors (main effects and/or interactions) using t-tests 
with an adjustment for false discovery rate (e.g., Bonferroni). Estimated marginal means (EMM) 
were used for reporting t-tests instead of unadjusted means. EMM are means that adjust for the 
various factors added to the linear mixed models. Untransformed means, transformed means, and 
EMM for all linear mixed model outcomes are reported in Appendix A. 
All analyses were conducted using SPSS V.25. We opted to use linear mixed models over 
repeated measures analyses of variance because linear mixed models can handle missing data (as 
noted in Data Preparation). Other advantages of linear mixed models include the ability to 
account for unequal spacing between time intervals and the ability to specify the variance-
covariance structure (Kwok et al., 2008). Thus, linear mixed models provide a more accurate 
estimate of associations between variables.  
Aim 2 Data Preparation and Analysis.  
Assumptions for the two-way analysis of variance (ANOVA) utilized here included the 
use of a continuous dependent variable, two independent variables with two or more independent 
groups, independence of observations (achieved by using means), a normally distributed 
dependent variable, and homogeneity of variance. All assumptions were met except the presence 
of an outlier. Based on the residual distribution of the dependent variable, one outlier was 
revealed and was subsequently excluded from this analysis.  
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To determine the interaction of cannabis use frequency and administration method on 
cannabis-related intoxication symptoms (model 1), we conducted a two-way ANOVA with two 
independent variables: overall cannabis frequency across the two weeks (summed cannabis use 
frequency, split into two groups [high frequency and low frequency] based on the response 
distribution) and cannabis administration method(s) used across the two weeks (combusted-only 
use, other-only use, combination of methods used). The other-only cannabis administration 
method sub-group had too few respondents (n = 1); therefore, this cannabis administration 
method sub-group was excluded from analyses. Therefore, due to the excluded case from data 
cleaning and the excluded case from the other-only cannabis method sub-group, the sample size 
for model 1 was 25. The dependent variable for model 1 was cannabis-related intoxication 
symptoms across two weeks. This variable was created by summing the scores of each 
intoxication symptom question for each time point to create a composite intoxication symptom 
score for each time point and then the sum scores were averaged across the two-week data 
collection period. Post-hoc tests were conducted with an appropriate adjustment for false 
discovery rate (i.e., Bonferroni adjustment). We expected that those who used other 
administration methods at the highest cannabis use frequencies across two weeks would report 
the highest intoxication symptoms relative to other method sub-groups.  
The two-way analysis of covariance (ANCOVA) shares many of the same assumptions as 
the two-way ANOVA. Additional two-way ANCOVA assumptions include the use of 
continuous covariates, a linear relationship between the covariate and dependent variable, 
homogeneity of regression slopes, and homogeneity of variances. All assumptions were met with 
three exceptions. There was one outlier, which was excluded from this analysis. Normality of the 
dependent variable was violated. As such, a square root transformation was conducted on the 
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dependent variable. Finally, the covariate was not linearly associated with the dependent 
variable; therefore, we proceeded with the analysis with caution.  
To determine the interaction of cannabis use frequency and cannabis administration 
method on cannabis-related respiratory symptoms (model 2), we conducted a two-way 
ANCOVA with two independent variables: overall cannabis frequency across the two weeks 
(summed cannabis use frequency, split into two groups [high frequency and low frequency] 
based on distribution) and cannabis administration method(s) used across the two weeks 
(combusted-only use, other-only use, combination of methods used).  The other-only cannabis 
administration method sub-group had too few respondents (n = 1); therefore, this sub-group was 
excluded from analyses. Therefore, due to the excluded case from data cleaning and the excluded 
case from the other-only cannabis administration method sub-group, the sample size for model 2 
was 25. The dependent variable for model 2 was square root adjusted cannabis-related 
respiratory symptoms across two weeks. This variable was created by summing the scores of 
each respiratory symptom question for each time point to create a composite respiratory 
symptom score for each time point. Then the sum scores were averaged across the two-week 
assessment period. The covariate was baseline respiratory symptoms (reported from the CCQ). 
Post-hoc tests were conducted with an appropriate adjustment for false discovery rate (i.e., 
Bonferroni adjustment).  
 
 
 
 
 
60 
 
 
 
Results 
Total Sample Descriptives 
In total, 40 participants were consented for the current study, and 27 were eligible for the 
study. Reasons for study exclusion included: past 30-day illicit substance use other than cannabis 
(n = 8), low cannabis use frequency (less than 5 days per week, n = 4), and high NIDA 
Modified-ASSIST score (greater than 27, n = 1). Of note, eligible and ineligible participants did 
not differ significantly in terms of baseline characteristics with the exception of age and total 
years of cannabis use (see Table 1). 
Eligible participants were mostly female (74.1%), and the average age was 19.8 years 
(SD = 1.2; see Table 1). The sample was racially diverse with 14 (51.9%) participants identifying 
as White or European-American, 5 (18.5%) participants identifying as Black, Afro-Caribbean, or 
African American, 3 (11.1%) participants identifying as Multiracial, 3 (11.1%) participants 
identifying as Asian American, and 2 (7.4%) identifying as Other. Of the entire sample, 2 (7.4%) 
identified as Hispanic/Latinx. Most participants (66.7%) indicated that they were a student, while 
25.9% were working and 7.4% were non-working or looking for work. Income level was widely 
distributed with 12 (44.4%) indicating that their income was $10,000 or less, 8 (29.6%) 
indicating their income was $10,000 to $59,000, and 7 (25.9%) indicating their income was over 
$60,000. Most participants (57.5%) self-reported that their health was “Excellent” or “Very 
good” and 42.5% indicated that their health was “Good” or “Fair”. The average baseline 
respiratory score was 9.67 (SD = 5.48), which indicates relatively low baseline negative 
respiratory symptom scores across the sample. Of the eligible participants, 21 (77.8%) had used 
any tobacco product in the past 30 days. Lifetime number of cannabis uses varied widely across 
participants with most (66.6%) having used cannabis between 101 to 2000 times in their lifetime.   
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Table 1. Demographic and substance history and use characteristics of the total consented 
participants, eligible participants, and ineligible participants. 
 
M (SD) or N (%) 
Total 
 (N=40) 
Eligible  
(N=27) 
Ineligible 
(N=13) 
 
p 
Demographics 
Age in years (M, SD) 20.18 (1.68) 19.81 (1.21) 20.92 (2.25) <0.05 
Gender    0.19 
Male 12 (30.0%) 7 (25.9%) 5 (38.5%)  
Female 27 (67.5%) 20 (74.1%) 7 (53.8%)  
Non-binary/Gender non-
conforming 
1 (2.5%) 0 (0.0%) 1 (7.7%)  
Race    0.42 
White or European-American 21 (52.5%) 14 (51.9%) 7 (53.8%)  
Black, Afro-Caribbean, or African 
American 
7 (17.5%) 5 (18.5%) 2 (15.4%)  
Multiracial 4 (10.0%) 3 (11.1%) 1 (7.7%)  
Asian American 3 (7.5%) 3 (11.1%) 0 (0.0%)  
Other 3 (7.5%) 2 (7.4%) 1 (7.7%)  
American Indian or Alaska Native 2 (5.0%) 0 (0.0%) 2 (15.4%)  
Hispanic/Latinx 4 (10.0%) 2 (7.4%) 2 (16.7%) 0.58 
Employment status    0.75 
Student  25 (62.5%) 18 (66.7%) 7 (53.8%)  
Working now 12 (30.0%) 7 (25.9%) 5 (38.5%)  
Non-working 3 (7.5%) 2 (7.4%) 1 (7.7%)  
Income    0.63 
Less than $10,000 17 (42.5%) 12 (44.4%) 5 (38.5%)  
$10,000-$59,000 14 (35.0%) 8 (29.6%) 6 (46.2%)  
$60,000 or more 9 (22.5%) 7 (25.9%) 2 (15.4%)  
General health    0.75 
Excellent/Very good 23 (57.5%) 15 (55.6%) 8 (61.5%)  
Good/Fair 17 (42.5%) 12 (44.4%) 5 (38.5%)  
Poor 0 (0.0%) 0 (0.0%) 0 (0.0%)  
Baseline respiratory score (M, SD) 9.00 (5.35) 9.67 (5.48) 7.50 (4.91) 0.25 
Past 30-day tobacco product use 
Any tobacco 31 (77.5%) 21 (77.8%) 10 (76.9%) 0.62 
Cigarette 9 (22.5%) 6 (22.2%) 3 (23.1%) 0.62 
Traditional cigar 6 (15.0%) 4 (14.8%) 2 (15.4%) 0.65 
Little cigar or cigarillo 13 (32.5%) 9 (33.3%) 4 (30.8%) 0.58 
Electronic cigarette 21 (52.5%) 14 (51.9%) 7 (53.8%) 0.59 
Hookah 7 (17.5%) 5 (18.5%) 2 (15.4%) 0.59 
Nicotine replacement therapy 2 (5.0%) 1 (3.7%) 1 (7.7%) 0.55 
Cannabis use and history 
Lifetime number of cannabis uses    0.47 
51-100 times 2 (5.0%) 0 (0.0%) 2 (15.4%)  
101-500 times 7 (17.5%) 5 (18.5%) 2 (15.4%)  
501-1000 times 8 (20.0%) 7 (25.9%) 1 (7.7%)  
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1001-2000 times 9 (22.5%) 6 (22.2%) 3 (23.1%)  
2001-5000 times 4 (10.0%) 3 (11.1%) 1 (7.7%)  
5001-10,000 times 7 (17.5%) 4 (14.8%) 3 (23.1%)  
More than 10,000 times 3 (7.5%) 2 (7.4%) 1 (7.7%)  
Lifetime joint use 37 (92.5%) 26 (96.3%) 11 (84.6%) 0.24 
Lifetime blunt use 39 (97.5%) 27 (100.0%) 12 (92.3%) 0.33 
Lifetime bowl/pipe use 35 (87.5%) 24 (88.9%) 11 (84.6%) 0.53 
Lifetime bong use 38 (95.0%) 26 (96.3%) 12 (92.3%) 0.55 
Lifetime vaporizer use 31 (77.5%) 21 (77.8%) 10 (76.9%) 0.62 
Lifetime dab use 29 (72.5%) 18 (66.7%) 11 (84.6%) 0.29 
Lifetime edible use 35 (87.5%) 25 (92.6%) 10 (76.9%) 0.31 
Total years of cannabis use (M, SD) 4.15 (2.16) 3.44 (1.28) 5.62 (2.84) <0.05 
Age of cannabis initiation in years 
(M, SD) 
15.77 (1.83) 16.04 (1.58) 15.23 (2.24) 0.20 
State of change (contemplation 
ladder) score (M, SD) 
N/A 4.81 (2.10) N/A N/A 
Note: Bold text indicates an alpha level of 0.05 or less. N/A indicates not applicable for this group. Zero participants 
indicated past 30-day use of pipe, chew, dip/snuff, snus or dissolvable tobacco products. Fisher’s Exact Test was used 
for all bivariate analyses due low cell counts except age, baseline respiratory score, total years of cannabis use, and age 
of cannabis initiation, which were analyzed with independent samples t-tests and perceived health, which was 
analyzed with Pearson chi-square. 
 
 
  
 
63 
 
 
 
Lifetime cannabis administration method use ranged between 66.7% (for dabs) and 100% (for 
blunts). All participants had used a blunt in their lifetime. Participants had been using cannabis 
on average for 3.44 years (SD = 1.28), and the average age of cannabis use initiation was 16.04 
years (SD = 1.58). Finally, the average state of cannabis change at the end of data collection was 
4.81 (SD = 2.10), indicating that participants were thinking about the way they use cannabis, but 
had no intentions to change their cannabis use patterns. In the cannabis ladder, the fourth rung 
stated “I sometimes think about the way that I use marijuana, but I have no plans to change it,” 
and the fifth rung stated “I often think about the way that I use marijuana, but I have no plans to 
change it.”  
Aim 1 Results 
All 27 eligible participants in the study were included in the analytical sample for Aim 1. 
A summary of linear mixed model results for Aim 1 (Models 1-4) is displayed in Table 2.  
Model 1: Cannabis hits frequency. The hypothesis that cannabis hits frequency would 
vary significantly by time of day was supported. There was a significant main effect of time of 
day (see Figure 4; F(2,988.16) = 16.17, p < 0.001). The hypothesis that cannabis hits frequency 
would be highest in the evenings and lowest in the mornings was partially supported. Most 
cannabis hits were consumed in the evenings and the fewest cannabis hits were consumed in the 
afternoons. Post hoc analyses indicated that there were significantly more cannabis hits 
consumed in the mornings (EMM = 1.26, SE = 0.14) compared to the afternoons (EMM = 0.95, 
SE = 0.14, p < 0.001, Bonferroni adjusted). Further, there were significantly more cannabis hits 
consumed in the evenings (EMM = 1.42, SE = 0.14) compared to the afternoons (EMM = 0.95, 
SE = 0.14, p < 0.001; Bonferroni adjusted).  
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Table 2. Statistical results summary for all linear mixed models in Aim 1.  
Note: Bold indicates a significant main effect or interaction with an alpha level of 0.05 or less. df are numerator and denominator degrees of 
freedom.
 Time of day Day of week Week Day of week X Week 
  df F p df F p df F p df F p 
Model 1             
Cannabis hits 
2, 
988.16 
16.17 <0.001 
6, 
988.08 
1.38 0.22 
1, 
987.80 
2.07 0.15 
6, 
987.86 
2.43 <0.05 
Model 2             
Number of cannabis 
administration methods 
used 
2, 
1004.56 
15.61 <0.001 
6, 
1004.45 
0.80 0.57 
1, 
1004.18 
4.32 <0.05 
6, 
1004.21 
3.12 0.05 
Model 3             
Intoxication scores 
2, 
988.56 
43.05 <0.001 
6, 
988.47 
0.93 0.47 
1, 
988.24 
0.34 0.56 
6, 
988.27 
2.17 <0.05 
Model 4             
Respiratory scores 
2, 
978.24 
2.19 0.11 
6, 
978.20 
1.55 0.16 
1, 
978.16 
11.52 <0.001 
6, 
978.14 
1.72 0.11 
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Figure 4. Estimated marginal means (+/- standard error of the mean; SEM) for number of 
cannabis hits (square root transformed) by time of day. Asterisks (***) indicate a significant 
difference between morning, afternoon, or evening (p < 0.001, Bonferroni adjusted).
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It was hypothesized that cannabis use frequency would be higher on the weekends 
compared to the weekdays; this hypothesis was not supported. However, there was a significant 
week by day of week interaction (See Figure 5; F(6,987.86) = 2.43, p < 0.05). Post hoc analyses 
indicated that on Mondays during week 1, cannabis hits consumed were significantly higher 
(EMM = 1.56, SE = 0.18) compared to week 2 (EMM = 1.14, SE = 0.18; p = 0.025; Bonferroni 
adjusted). On Thursdays during week 1, cannabis hits consumed were significantly higher (EMM 
= 1.35, SE = 0.18) compared to week 2 (EMM = 0.95, SE = 0.19; p = 0.035; Bonferroni 
adjusted). On Sundays during week 1, cannabis hits consumed were significantly lower (EMM = 
0.91, SE = 0.18) compared to week 2 (EMM = 1.32, SE = 0.18; final day of data collection; p = 
0.026; Bonferroni adjusted). Within weeks, during week 1, cannabis hits consumed were 
significantly higher on Monday (EMM = 1.56, SE = 0.18) compared to Sunday (EMM = 0.91, 
SE = 0.18; p = 0.01; Bonferroni adjusted). 
Model 2: Number of cannabis administration methods used. It was hypothesized that 
the number of cannabis administration methods used would vary significantly by time of day and 
day of the week, and this hypothesis was partially supported. There was a significant main effect 
of time of day (see Figure 6; F(2,1004.56) = 15.61, p < 0.001), but there was insufficient 
evidence to indicate a main effect of day of the week. Post hoc analyses indicated, in the 
mornings, the number of cannabis administration methods was significantly higher (EMM = 
0.56, SE = 0.05) compared to the afternoons (EMM = 0.46, SE = 0.05; p < 0.001; Bonferroni 
adjusted). In the evenings, the number of cannabis administration methods used was significantly 
higher (EMM = 0.66, SE = 0.05) compared to afternoons (EMM = 0.46, SE = 0.05; p < 0.001; 
Bonferroni adjusted) and compared to the mornings (EMM = 0.56, SE = 0.05; p < 0.001; 
Bonferroni adjusted). 
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Figure 5. Estimated marginal means (+/-SEM) for number of cannabis hits (square root 
transformed) by week and day of week. Asterisks (*) indicate a significant difference between 
week 1 and week 2 (p < 0.05, Bonferroni adjusted). 
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Figure 6. Estimated marginal means (+/-SEM) for number of cannabis administration methods 
used (square root transformed) by time of day. Asterisks (***) indicate a significant difference 
between morning, afternoon, or evening (p < 0.001, Bonferroni adjusted). 
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Exploratory analyses indicated that there was a significant main effect of week on the 
number of cannabis administration methods used (see Figure 7; F(1,1004.18) = 4.32, p < 0.05). 
Post hoc analyses indicated that, during week 1, the number of cannabis administration methods 
used were significantly higher (EMM = 0.59, SE = 0.05) compared to week 2 (EMM = 0.53, SE 
= 0.05; p = 0.038; Bonferroni adjusted). Exploratory analyses also indicated that there was a 
significant week by day of week interaction on the number of cannabis administration methods 
used (see Figure 8; F(6,1004.21) = 3.12, p < 0.05). Post hoc analyses indicated that on Tuesdays 
of week 1, the number of cannabis administration methods used was significantly higher (EMM 
= 0.65, SE = 0.07) compared to week 2 (EMM = 0.43, SE = 0.07; p = 0.012; Bonferroni 
adjusted). On Thursdays during week 1, the number of cannabis administration methods was 
significantly higher (EMM = 0.65, SE = 0.07) compared to week 2 (EMM = 0.46, SE = 0.07; p = 
0.015; Bonferroni adjusted). On Sundays during week 1, the number of cannabis administration 
methods used was significantly lower (EMM = 0.41, SE = 0.07) compared to week 2 (EMM = 
0.60, SE = 0.07; p = 0.017; Bonferroni adjusted). Within weeks, during week 1, the number of 
cannabis administration methods used was significantly higher on Monday (EMM = 0.68, SE = 
0.07) and Thursday (EMM = 0.65, SE = 0.07) compared to Sunday (EMM = 0.41, SE = 0.07; p = 
0.018; Bonferroni adjusted). 
Model 3: Intoxication scores. It was hypothesized that cannabis-related intoxication 
symptoms would vary significantly by time of day, such that intoxication symptoms would be 
highest in the evenings and lowest in the mornings. This hypothesis was supported; there was a 
significant main effect of time of day (see Figure 9; F(2,988.56) = 43.05, p < 0.001).  
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Figure 7. Estimated marginal means (+/-SEM) for number of cannabis administration methods 
used (square root transformed) by week. Asterisks (***) indicate a significant difference 
between week 1 and week 2 (p < 0.001, Bonferroni adjusted). 
 
1 2
0.45
0.50
0.55
0.60
0.65
Number of Cannabis Administration Methods Used by  Week
Week
N
u
m
b
er
 o
f 
M
et
h
o
d
s 
U
se
d
(S
q
u
a
re
 R
o
o
t 
T
ra
n
sf
o
rm
ed
)
✱✱✱
 
71 
 
 
 
 
Figure 8. Estimated marginal means (+/-SEM) for number of cannabis administration methods 
used (square root transformed) by week and day of week. Asterisks (*) indicate a significant 
difference between week 1 and week 2 (p < 0.05, Bonferroni adjusted). 
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Figure 9. Estimated marginal means (+/-SEM) for summed intoxication scores (square root 
transformed) by time of day. Asterisks (***) indicate a significant difference between morning, 
afternoon, or evening (p < 0.001, Bonferroni adjusted). 
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Post hoc analyses indicated that in the afternoons, intoxication symptom scores were 
significantly higher (EMM = 0.70, SE = 0.09) compared to mornings (EMM = 0.50, SE = 0.09; p 
< 0.001; Bonferroni adjusted). In the evenings, intoxication symptom scores were significantly 
higher (EMM = 1.06, SE = 0.09) compared to mornings (EMM = 0.50, SE = 0.09; p < 0.001; 
Bonferroni adjusted) and compared to afternoons (EMM = 0.70, SE = 0.09; p < 0.001; 
Bonferroni adjusted). 
It was hypothesized that cannabis-related intoxication symptoms would vary significantly 
by day of week, such that intoxication symptoms would be highest on the weekends compared to 
weekdays. There was insufficient evidence to suggest that this hypothesis was supported. 
However, there was a significant week by day of week interaction (see Figure 10; F(6,988.27) = 
2.17, p = 0.05). Post hoc analyses indicated that on Thursdays of week 1, intoxication symptom 
scores were significantly higher (EMM = 0.88, SE = 0.13) compared to week 2 (EMM = 0.56, 
SE = 0.13; p = 0.016; Bonferroni adjusted). On Sundays of week 1, intoxication symptom scores 
were significantly lower (EMM = 0.54, SE = 0.13) compared to week 2 (EMM = 0.84, SE = 
0.12; p = 0.025; Bonferroni adjusted).  
Model 4: Respiratory scores. It was hypothesized that cannabis-related respiratory 
symptoms would vary significantly by day of week and time of day, such that respiratory 
symptoms would be highest in the evenings and on the weekends compared to mornings and on 
the weekdays. Results did not support this hypothesis. Instead, results indicated that there was a 
significant main effect of week (see Figure 11; F(1,978.16) = 11.52, p < 0.001), but not day of 
week or time of day. Post hoc analyses indicated that during week 1, respiratory symptom scores 
were significantly higher (EMM = 1.07, SE = 0.15) compared to week 2 (EMM = 0.91, SE = 
0.15; p = 0.001; Bonferroni adjusted).   
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Figure 10. Estimated marginal means (+/-SEM) for summed intoxication scores (square root 
transformed) by week and day of week. Asterisks (*) indicate a significant difference between 
week 1 and week 2 (p < 0.05, Bonferroni adjusted).  
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Figure 11. Estimated marginal means (+/-SEM) for summed respiratory symptom scores (square 
root transformed) by week. Asterisks (*) indicate a significant difference between week 1 and 
week 2 (p < 0.05, Bonferroni adjusted).  
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Aim 2, Hypothesis 2a Results 
Characteristics of the overall analytical sample (n = 25), cannabis administration method 
sub-group (i.e., combusted-only and combination), and hits frequency sub-group (i.e., low hits 
frequency and high hits frequency) samples for Hypothesis 2a are displayed in Table 3. Over half 
of participants (n = 14, 56.0%) were classified into the combusted-only cannabis administration 
method sub-group and 11 (44.0%) were classified into the combination cannabis administration 
method sub-group. Among those in the combusted-only cannabis administration method sub-
group, bowl/pipe and bong were the most prevalent methods used during the study (endorsed by 
> 71.4%), and blunt (35.7%) and joint (57.1%) were the least common methods used during the 
study. Among those in the combination cannabis administration method sub-group, during the 
study, bong and vaporizer use were the most common methods reported (endorsed by > 72.7%), 
and blunt (45.5%) was the least prevalent method endorsed during the study. Approximately half 
of participants (n = 12, 48.0%) were classified into the low hits frequency sub-group and 13 
(52.0%) participants were classified into the high hits frequency sub-group. The average number 
of total summed hits consumed during the study among the low hits frequency sub-group was 
54.9 (SD = 26.1), and among the high hits frequency sub-group, the average number of total 
summed hits consumed was 185.1 (94.1). See additional descriptives in Table 3.  
A 2x2 between-groups ANOVA was conducted to test the main effects and potential 
interaction between sub-groups of cannabis administration method and sub-groups of cannabis 
use frequency (high vs. low sub-groups) on mean cannabis-related intoxication symptom scores 
facross two weeks. The independent variables were sub-group of cannabis administration method 
(combustion vs. combination) and frequency of cannabis use measured in hits (high vs. low sub-
groups).  
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Table 3. Aim 2, Characteristics of the overall, cannabis administration method sub-group, and hits 
frequency sub-group samples used for Hypothesis 2a.  
 
M (SD) or N (%) 
Overall  
(n = 25) 
 
Combusted
-only  
(n = 14) 
Combination 
(n = 11) 
 
Low hits 
frequency  
(n = 12) 
High hits 
frequency  
(n = 13) 
Demographics 
Age in years (M, SD) 19.8 (1.3)  19.8 (1.1) 19.8 (1.5)  20.1 (1.4) 19.5 (1.1) 
Gender         
Male 6 (24.0%)  2 (14.3%) 4 (36.4%)  3 (25.0%) 3 (23.1%) 
Female 19 (76.0%)  12 (85.7%) 7 (63.6%)  9 (75.0%) 10 (76.9%) 
Race        
White or European-
American 
12 (48.0%)  5 (35.7%) 7 (63.6%)  4 (33.3%) 8 (61.5%) 
Black, Afro-Caribbean, 
or African American 
5 (20.0%)  4 (28.6%) 1 (9.1%)  4 (33.3%) 1 (7.7%) 
Multiracial 3 (12.0%)  1 (7.1%) 2 (18.2%)  2 (16.7%) 1 (7.7%) 
Asian American 3 (12.0%)  2 (14.3%) 1 (9.1%)  1 (8.3%) 2 (15.4%) 
Other 2 (8.0%)  2 (14.3%) 0 (0.0%)  1 (8.3%) 1 (7.7%) 
Hispanic/Latinx 2 (8.0%)  1 (7.1%) 1 (9.1%)  2 (16.7%) 0 (0.0%) 
Employment status        
Student  16 (64.0%)  8 (57.1%) 8 (72.7%)  6 (50.0%) 10 (76.9%) 
Working 7 (28.0%)  5 (35.7%) 2 (18.2%)  4 (33.3%) 3 (23.1%) 
Non-working 2 (8.0%)  1 (7.1%) 1 (9.1%)  2 (16.7%) 0 (0.0%) 
Income        
Less than $10,000 11 (44.0%)  8 (57.1%) 3 (27.3%)  5 (41.7%) 6 (46.2%) 
$10,000-$59,000 7 (28.0%)  3 (21.4%) 4 (36.4%)  5 (41.7%) 2 (15.4%) 
$60,000 or more 7 (28.0%)  3 (21.4%) 4 (36.4%)  2 (16.7%) 5 (38.5%) 
General health        
Excellent/Very good 14 (56.0%)  8 (57.1%) 6 (54.5%)  8 (66.7%) 6 (46.2%) 
Good/Fair 11 (44.0%)  6 (42.9%) 5 (45.5%)  4 (33.3%) 7 (53.8%) 
Poor 0 (0.0%)  0 (0.0%) 0 (0.0%)  0 (0.0%) 0 (0.0%) 
Past 30-day tobacco product use 
Any tobacco 20 (80.0%)  11 (78.6%) 9 (81.8%)  10 (83.3%) 10 (76.9%) 
Cigarette 6 (24.0%)  4 (28.6%) 2 (18.2%)  4 (33.3%) 2 (15.4%) 
Traditional cigar 4 (16.0%)  2 (14.3%) 2 (18.2%)  2 (16.7%) 2 (15.4%) 
Little cigar or cigarillo 9 (36.0%)  5 (35.7%) 4 (36.4%)  4 (33.3%) 5 (38.5%) 
Electronic cigarette 13 (52.0%)  7 (50.0%) 6 (54.5%)  5 (41.7%) 8 (61.5%) 
Hookah 5 (20.0%)  3 (21.4%) 2 (18.2%)  2 (16.7%) 3 (23.1%) 
Nicotine replacement 
therapy 
1 (4.0%)  1 (7.1%) 0 (0.0%)  0 (0.0%) 1 (7.7%) 
Cannabis use history and study cannabis use 
Total years of cannabis 
use (M, SD) 
3.4 (1.2)  2.9 (0.9) 3.9 (1.4)  6.4 (1.6) 3.7 (1.2) 
Age of cannabis 
initiation (M, SD) 
16.1 (1.6)  16.4 (1.2) 15.7 (2.0)  16.5 (1.4) 15.7 (1.7) 
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Total summed hits 
during study (M, SD) 
122.6 
(95.6) 
 85.8 (57.3) 
169.5 
(115.6) 
 54.9 (26.1) 
185.1 
(94.1) 
Study joint use 14 (56.0%)  8 (57.1%) 6 (54.5%)  6 (50.0%) 8 (61.5%) 
Study blunt use 10 (40.0%)  5 (35.7%) 5 (45.5%)  3 (25.0%) 7 (53.8%) 
Study bowl/pipe use 16 (64.0%)  10 (71.4%) 6 (54.5%)  7 (58.3%) 9 (69.2%) 
Study bong use 20 (80.0%)  11 (78.6%) 9 (81.8%)  9 (75.0%) 11 (84.6%) 
Study vaporizer use 8 (32.0%)  0 (0.0%) 8 (72.7%)  4 (33.3%) 4 (30.8%) 
Study dab use 6 (24.0%)  0 (0.0%) 6 (54.5%)  0 (0.0%) 6 (46.2%) 
Study edible use 6 (24.0%)  3 (21.4%) 3 (27.3%)  2 (16.7%) 4 (30.8%) 
Note: Results are based upon individuals who met assumptions based on their summed intoxication scores 
and who were included in the combusted-only or combination cannabis administration method sub-groups 
(n = 25). 
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The dependent variable was mean cannabis-related intoxication symptom scores across the two 
weeks. It was hypothesized originally that those who use other administration methods at high 
frequencies will have the highest intoxication symptoms relative to combusted and combination 
administration method sub-groups. However, the proposed hypothesis could not be conducted 
due to few participants in the other administration method sub-group. As such, the results to test 
for differences between the combusted-only and combination administration method sub-groups 
on cannabis-related intoxication symptoms are described.  
 There was a significant main effect of cannabis use frequency on mean cannabis-related 
intoxication symptom scores (F(1,21) = 31.38, p < 0.001), such that for high frequency cannabis 
users, intoxication symptom scores were significantly higher (EMM = 2.03, SE = 0.16) 
compared to low frequency cannabis users (EMM = 0.69, SE = 0.18). There was insufficient 
evidence to suggest that there was a main effect of cannabis administration method sub-group on 
average cannabis-related intoxication symptom scores, (F(1,21) = 2.19, p = 0.15). Further, there 
was insufficient evidence to suggest that there was an interaction between cannabis use 
frequency and cannabis administration method sub-group on average cannabis-related 
intoxication symptom scores, (F(1,21) = 2.91, p = 0.10). Despite this finding, due to the low 
sample size, exploratory nature of the study, and EMM among the variables of interest (see 
Figure 12), pairwise comparisons among the interaction model were probed.  Post-hoc 
comparisons indicated that among only high frequency cannabis users, mean intoxication 
symptom scores were significantly lower in the combusted-only cannabis administration method 
group (EMM = 1.65, SE = 0.24) compared to the combination cannabis administration method 
group (EMM = 2.41, SE = 0.22; p < 0.05; Bonferroni-adjusted).  
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Figure 12. Estimated marginal means (+/-SEM) for intoxication symptom scores across cannabis 
hits frequency sub-group and administration method sub-group. Asterisks (*) indicate a 
significant difference in intoxication symptoms between combusted-only and combination 
administration method sub-groups among only the high frequency cannabis use group (p < 0.05, 
Bonferroni adjusted).  
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Aim 2, Hypothesis 2b Results 
Characteristics of the overall analytical sample (n = 25), cannabis administration method 
sub-groups (i.e., combusted-only and combination), and hits frequency sub-groups (i.e., low hits 
frequency and high hits frequency) for Hypothesis 2b are displayed in Table 4. The combusted-
only and combination cannabis administration method sub-groups, as well as the high and low 
cannabis hits frequency sub-groups for Aim 2, Hypothesis 2b were very similar to the groups in 
Aim 2, Hypothesis 2a (with the exception of 2 participants). As such, to read more detailed 
descriptions of these groups, see Aim 2, Hypothesis 2a Results. To see specific descriptives for 
Aim 2, Hypothesis 2b, see Table 4.  
For Aim 2, Hypothesis 2b, a 2x2 between-groups ANCOVA was conducted to test the 
main effects and potential interaction between sub-groups of cannabis administration method and 
frequency of cannabis use (measured in hits) on mean cannabis-related respiratory symptom 
scores across two weeks. The independent variables were sub-group of cannabis administration 
method (i.e., combustion vs combination sub-groups) and frequency of cannabis use measured in 
hits (i.e., high vs. low sub-groups). The dependent variable was mean cannabis-related 
respiratory symptom scores across the two weeks. The covariate was baseline respiratory score 
from the CCQ. It was hypothesized that those who use combusted administration methods and at 
the highest frequencies would report the highest negative respiratory symptoms relative to other 
and combination cannabis administration method sub-groups. Similar to Aim 2, Hypothesis 2a, 
the other cannabis administration method sub-group was not included in this analysis due to low 
sample size. Therefore, the results to test for differences between the combusted and 
combination cannabis administration method sub-groups on cannabis-related respiratory 
symptom scores are described 
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Table 4. Aim 2, Characteristics of the overall, cannabis administration method sub-group, and hits 
frequency sub-group samples used for Hypothesis 2b. 
M (SD) or N (%) 
Overall  
(n = 25) 
 
Combusted 
-only  
(n = 13) 
Combination  
(n = 12) 
 
Low hits 
frequency  
(n = 12) 
High hits 
frequency  
(n = 13) 
Demographics 
Age in years (M, SD) 19.8 (1.2)  19.8 (1.2) 19.8 (1.4)  20.1 (1.4) 19.5 (1.1) 
Gender        
Male 7 (28.0%)  2 (15.4%) 5 (41.7%)  4 (33.3%) 3 (23.1%) 
Female 18 (72.0%)  11 (84.6%) 7 (58.3%)  8 (66.7%) 10 (76.9%) 
Race        
White or European-
American 
12 (48.0%)  4 (30.8%) 8 (66.7%)  4 (33.3%) 8 (61.5%) 
Black, Afro-Caribbean, 
or African American 
5 (20.0%)  4 (30.8%) 1 (8.3%)  4 (33.3%) 1 (7.7%) 
Multiracial 3 (12.0%)  1 (7.7%) 2 (16.7%)  2 (16.7%) 1 (7.7%) 
Asian American  3 (12.0%)  2 (15.4%) 1 (8.3%)  1 (8.3%) 2 (15.4%) 
Other 2 (8.0%)  2 (15.4%) 0 (0.0%)  1 (8.3%) 1 (7.7%) 
Hispanic/Latinx 2 (8.0%)  1 (7.7%) 1 (8.3%)  2 (16.7%) 0 (0.0%) 
Employment status        
Student  17 (68.0%)  8 (61.5%) 9 (75.0%)  7 (58.3%) 10 (76.9%) 
Working now 6 (24.0%)  4 (30.8%) 2 (16.7%)  3 (25.0%) 3 (23.1%) 
Non-working 2 (8.0%)  1 (7.7%) 1 (8.3%)  2 (16.7%) 0 (0.0%) 
Income        
Less than $10,000 10 (40.0%)  7 (53.8%) 3 (25.0%)  4 (33.3%) 6 (46.2%) 
$10,000-$59,000 8 (32.0%)  3 (23.1%) 5 (41.7%)  6 (50.0%) 2 (15.4%) 
$60,000 or more 7 (28.0%)  3 (23.1%) 4 (33.3%)  2 (16.7%) 5 (38.5%) 
General health        
Excellent/Very good 14 (56.0%)  8 (61.5%) 6 (50.0%)  8 (66.7%) 6 (46.2%) 
Good/Fair 11 (44.0%)  5 (38.5%) 6 (50.0%)  4 (33.3%) 7 (53.8%) 
Poor 0 (0.0%)  0 (0.0%) 0 (0.0%)  0 (0.0%) 0 (0.0%) 
Baseline respiratory 
score (M, SD) 
9.5 (5.6)  8.8 (3.5) 10.3 (7.4)  10.0 (5.3) 9.1 (6.1) 
Past 30-day tobacco product use 
Any tobacco 20 (80.0%)  10 (76.9%) 10 (83.3%)  10 (83.3%) 10 (76.9%) 
Cigarette 6 (24.0%)  4 (30.8%) 2 (16.7%)  4 (33.3%) 2 (15.4%) 
Traditional cigar 4 (16.0%)  2 (15.4%) 2 (16.7%)  2 (16.7%) 2 (15.4%) 
Little cigar or cigarillo 9 (36.0%)  5 (38.5%) 4 (33.3%)  4 (33.3%) 5 (38.5%) 
Electronic cigarette 13 (52.0%)  6 (46.2%) 7 (58.3%)  5 (41.7%) 8 (61.5%) 
Hookah 5 (20.0%)  3 (23.1%) 2 (16.7%)  2 (16.7%) 3 (23.1%) 
Nicotine replacement 
therapy 
1 (4.0%)  1 (7.7%) 0 (0.0%)  0 (0.0%) 1 (7.7%) 
Cannabis use history and study cannabis use 
Total years of cannabis 
use (M, SD) 
3.3 (1.2)  2.9 (0.9) 3.8 (1.3)  2.9 (1.2) 3.7 (1.2) 
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Age of cannabis 
initiation (M, SD) 
16.2 (1.6)  16.5 (1.2) 15.8 (1.9)  16.7 (1.4) 15.7 (1.7) 
Total summed hits in 
study (M, SD) 
123.6 
(95.0) 
 88.1 (59.0) 
162.2 
(113.1) 
 57.0 (27.1) 
185.2 
(94.1) 
Study joint use 13 (52.0%)  7 (53.8%) 6 (50.0%)  5 (41.7%) 8 (61.5%) 
Study blunt use 9 (36.0%)  4 (30.8%) 5 (41.7%)  2 (16.7%) 7 (53.8%) 
Study bowl/pipe use 17 (68.0%)  10 (76.9%) 7 (58.3%)  8 (66.7%) 9 (69.2%) 
Study bong use 20 (80.0%)  10 (76.9%) 10 (83.3%)  9 (75.0%) 11 (84.6%) 
Study vaporizer use 9 (36.0%)  0 (0.0%) 9 (75.0%)  5 (41.7%) 2 (30.8%) 
Study dab use 6 (24.0%)  0 (0.0%) 6 (50.0%)  0 (0.0%) 6 (46.2%) 
Study edible use 6 (24.0%)  3 (23.1%) 3 (25.0%)  2 (16.7%) 4 (30.8%) 
Note: Results are based upon individuals who met assumptions based on their summed respiratory 
symptom scores and who were included in the combusted-only or combination cannabis 
administration method sub-groups (n = 25). 
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 After adjusting for baseline respiratory symptoms, there was insufficient evidence to 
suggest a main effect of high frequency cannabis use (EMM = 1.38, SE = 0.16) and low 
frequency cannabis use (EMM = 1.01, SE = 0.17) on respiratory symptom scores (F(1,20) = 
2.40, p = 0.14). There was insufficient evidence to suggest that there was a main effect of 
combusted cannabis administration method use (EMM = 1.24, SE = 0.16) and combination 
cannabis administration method use (EMM = 1.15, SE = 0.17) on average cannabis-related 
respiratory symptom scores after controlling for baseline respiratory symptoms, (F(1,20) = 
0.148, p = 0.704). There was insufficient evidence to suggest that there was an interaction 
between cannabis use frequency and cannabis administration method sub-group on average 
respiratory symptoms after controlling for baseline respiratory symptoms, (F(1,20) = 0.74, p = 
0.40). Despite this finding, due to the low sample size, exploratory nature of the study, and 
EMMs among the variables of interest (see Figure 13), post-hoc comparisons among the 
interaction model were probed using a Bonferroni adjustment; however, no significant mean 
differences were revealed.  
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Figure 13. Estimated marginal means (+/-SEM) for respiratory symptoms across cannabis hit 
frequency sub-group and administration method sub-group.  
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Discussion 
 The purpose of this two-week EMA study among young adult heavy cannabis users was 
to characterize within week and day patterns of cannabis use frequency, number of cannabis 
administration methods used, and cannabis-related intoxication and respiratory symptoms and to 
test the interaction of cannabis use frequency and cannabis administration method use on 
cannabis-related intoxication and respiratory symptoms.  
For Aim 1, it was hypothesized that cannabis use frequency would be lowest in the 
mornings and highest in the evenings. Results indicated that cannabis use frequency was highest 
in the evenings and lowest in the afternoons. It was hypothesized that cannabis use frequency 
would be higher on the weekends compared to the weekdays. Results did not support this 
hypothesis, but there were some differences in cannabis use frequency between weeks 1 and 2 of 
data collection, and during week 1, more hits were consumed on Monday compared to Sunday. It 
was hypothesized that the number of cannabis administration methods would vary by day of 
week and time of day. Results indicated that the number of cannabis administration methods was 
highest in the evenings, followed by mornings and afternoons. There was no indication that 
number of cannabis administration methods varied significantly by day of week. However, some 
evidence suggested that the number of cannabis administration methods used on some days of 
the week differed by week. Finally, it was hypothesized that cannabis-related intoxication and 
respiratory symptoms would vary significantly by day of week and time of day. Results indicated 
that intoxication symptoms were highest in the evenings, followed by afternoons and mornings. 
Results also indicated that intoxication symptoms significantly differed on some days of the 
week by week. There was no indication that intoxication symptoms significantly differed by day 
of week. Respiratory scores did not significantly differ by day of week or time of day, as 
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hypothesized; however, there was evidence that respiratory scores differed by week, such that 
week 1 had higher respiratory symptom reports compared to week 2.  
For Aim 2, results indicated that high cannabis hits frequency users reported significantly 
higher average intoxication symptoms compared to low hits frequency users. Exploratory 
analyses indicated that among only those in the high cannabis hits frequency use group, 
combination cannabis administration method sub-group users reported higher intoxication 
compared to the combusted-only cannabis administration method sub-group. Finally, it was 
hypothesized that those who used combusted cannabis administration methods at the highest 
frequencies would report the highest respiratory symptoms relative to the combination cannabis 
administration method sub-group. There was no evidence to suggest a difference in respiratory 
symptoms among cannabis administration method sub-groups or cannabis hits frequency sub-
groups.  
 Based on the results of the current study, cannabis use frequency by time of day and day 
of week was consistent with some previous literature on cannabis use among heavy cannabis 
users. Cannabis use was highest in the evenings in the current study, which was similar to results 
from a previous EMA study among young adults in the US who reported cannabis use for one 
week using palm pilots (Treloar Padovano & Miranda, 2018). Results from the same study and 
from the current study failed to find evidence that cannabis use frequency differed by day of the 
week (Treloar Padovano & Miranda, 2018). These results are inconsistent with another EMA 
study among US adult heavy cannabis users who reported daily cannabis use for three months by 
using an Interactive Voice Response (i.e., phone call) system (Hughes et al., 2014). Results from 
this study indicated that weekend cannabis use was higher compared to weekdays (Hughes et al., 
2014). Findings may have differed across these three studies due to differences in participant age 
 
88 
 
 
 
or employment/student status. In Treolar Padovano and Miranda (2018), participant ages ranged 
from 15 – 24 years, and employment/student status was not reported; however, due to the 
inclusion of participants under 18 years in the US, it is presumed that many participants were in 
high school. In the current study, age ranged from 18-25 years, and most participants were 
college students (66.7%); whereas, in Hughes et al. (2014), the average participant age was 33 
years, and 48% of participants were employed. These data may be an indication that those who 
are older in age (i.e., older than average US high school or college age) or who are employed 
may use cannabis more on the weekends compared to weekdays due to weekday obligations for 
which cannabis use may interfere negatively, such as employment (Macdonald et al., 2010). For 
those who are younger or are in high school or college, these data may be an indication that these 
groups have more flexibility or have fewer obligations for which cannabis use may interfere 
negatively. These findings highlight the importance of interventionists to consider the time that 
cannabis use occurs (i.e., days of week and times of day), targeted cannabis user age, and 
contexts of cannabis use (e.g., during work or school obligations).  
Results from the current study indicated that the number of cannabis administration 
methods used was highest in the evenings, followed by mornings and afternoons. These results 
are novel; no previous studies have identified number of cannabis administration methods used 
across time of day. The pattern of more cannabis administration methods used during the 
evenings, followed by mornings and afternoons was consistent with the cannabis use frequency 
data from the current study. Although this specific finding is novel, results from the current study 
and previous research are consistent with previous literature in that use of multiple cannabis 
administration methods is common among young adult heavy cannabis users (Hughes et al., 
2014; Rudy, 2018; Schauer et al., 2016). Further, previous studies have relied on cannabis use 
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reports from the past 30 days wherein use of multiple cannabis administration methods were 
reported (Rudy, 2018; Schauer et al., 2016). However, the current study relied on past two-week 
reports, indicating that young adult heavy cannabis users may be performing more risky 
behaviors by using more cannabis administration methods in more concentrated time spans (i.e., 
use of multiple cannabis administration methods over two weeks compared to four weeks) than 
previously known. These findings showcase an immediate need to understand the safety of using 
numerous cannabis administration methods and the health implications of using multiple 
cannabis administration methods within shorter timeframes than previously identified.  
Data from the current study suggest that cannabis use is highest in the morning, decreases 
in the afternoon, and increases again in the evening. Users reported more cannabis use in the 
mornings and evenings possibly due to acute withdrawal effects, including irritability and 
anxiety, experienced overnight and during the afternoons. The psychological effects of cannabis 
can last anywhere from 2-12 hours depending on the route of administration (i.e., oral vs. 
inhaled; Grotenhermen, 2003). After the psychological effects diminish, withdrawal symptoms 
begin. Over the course of the night, while cannabis users are sleeping, they likely begin 
experiencing acute withdrawal effects. Overnight withdrawal effects may explain the frequency 
of morning cannabis use observed in the current study. Cannabis users may continue to 
experience the psychological effects of their cannabis use throughout the morning into the 
afternoon. However, when evening time arrives, cannabis users may begin to experience 
withdrawal symptoms once more and use cannabis to avoid those symptoms. 
Other novel results from the current study indicated that cannabis-related intoxication 
symptoms were highest in the evenings, followed by afternoons and mornings. These findings 
suggest that intoxication symptoms increased throughout the day; a pattern not studied 
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previously in the literature. Interestingly, intoxication symptoms did not follow the same patterns 
associated with cannabis use frequency or number of cannabis administration methods used, 
which indicated the greatest intensity of use in the evenings, followed by mornings, and 
afternoons. Although all three outcomes were highest in the evenings, intoxication may have 
been lowest in the mornings due to intoxication effects diminishing while participants slept. The 
effect of sleep on intoxication is plausible because the average time for subjective cannabis drug 
effects to extinguish after inhaled cannabis administration is 8 hours (e.g., Spindle et al., 2018). 
In the current study, the baseline average number of hours spent sleeping was 7 hours (SD = 
0.82), which explains the low reports of cannabis-related intoxication symptoms in the mornings. 
An increase in self-reported intoxication symptoms throughout the day has important 
implications. High intoxication in the evenings among heavy cannabis users could indicate that 
other risky behaviors, such as the use of other illicit substances or intoxicated driving, may also 
occur during the evenings in conjunction with cannabis use. The current study excluded those 
who reported past 30-day use of other illicit substances; however, future studies should seek to 
include groups who engage in high risk behaviors in order to understand how cannabis-related 
intoxication symptoms interact with the use of other illicit substances or other risky behaviors.  
Results from the current study indicated that high frequency cannabis users reported 
significantly higher average intoxication symptoms compared to low frequency users; another 
finding that has not been reported in previous literature. Although these specific results have not 
been observed before, other forms of evidence indicate that self-reported cannabis intoxication 
symptoms are highest shortly after cannabis use (Spindle et al., 2018; Treloar Padovano & 
Miranda, 2018). Results from an EMA study of US young adult cannabis users who self-reported 
cannabis intoxication symptoms on a daily basis for one week indicated that intoxication was 
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highest after cannabis use, but more fine-detailed assessments of intoxication by time of day or 
use frequency were not assessed or reported (Treloar Padovano & Miranda, 2018). Similarly, 
results from a clinical laboratory study in which US adult cannabis users were administered 
vaporized and smoked cannabis indicated that self-reported cannabis intoxication was highest 
immediately following cannabis administration (i.e., 10 minutes after drug administration) in 
both vaporized and smoked cannabis conditions compared to 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours 
following drug administration (Spindle et al., 2018). In sum, previous literature indicates that 
cannabis intoxication is highest immediately following cannabis administration. Findings from 
previous studies contextualize the current results because high frequency cannabis users likely 
remain more intoxicated throughout the day due to less time between drug administrations 
compared to low frequency cannabis users who allow more time to pass between cannabis uses, 
resulting in lower average intoxication symptoms among this group.  
Another novel finding from the current study was that among only those in the high 
frequency use group, combination cannabis administration method sub-group users (i.e., those 
who use any combination of cannabis administration methods excluding edibles) reported higher 
cannabis-related intoxication symptoms compared to the combusted-only cannabis 
administration method sub-group users (i.e., those who use only joints, blunts, pipes/bowls, 
and/or bongs). Although this result is exploratory and should be tested further, these findings are 
consistent with previous literature. Results from an online survey from 2014-2015 indicated that 
US adult cannabis users reported higher intoxication symptoms when using a vaporizer with 
cannabis compared to smoking cannabis (Lee et al., 2016). Similarly, US adult dab users from an 
online survey in 2014 reported higher intoxication symptoms from dabs compared to other 
cannabis administration methods (M. Loflin & Earleywine, 2014). These results should be 
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further studied by measuring the intoxication effects from individual cannabis administration 
methods using behavioral measures, field sobriety tests, and biological measurements in 
controlled clinical laboratory settings. Another important component of understanding the 
relationship between cannabis use behavior and cannabis intoxication is measuring the THC 
content of used cannabis. As such, the accurate measurement of THC content of cannabis used 
by participants in their natural environment is essential to understand more fully patterns of 
cannabis use behavior and associated intoxication/impairment.  
Respiratory scores did not significantly differ by day of week or time of day, as 
hypothesized. Although these results are surprising when compared to previous literature, the 
current findings are consistent with other results from the current study, given the lack of main 
effects by day of week on cannabis use frequency, number of cannabis administration methods 
used, or cannabis-related intoxication symptoms observed. However, due to the main effects of 
time of day observed in other results from the current study, an absence of a main effect of time 
of day on respiratory symptoms was unexpected. These findings were also surprising because 
previous literature indicates that cannabis users experience a higher incidence of negative 
respiratory symptoms as a result of their cannabis use (Aldington et al., 2007; Ribeiro & Ind, 
2016). One potential reason for this disparity could be the chosen measures used to assess 
respiratory symptoms. The three questions used to measure respiratory symptoms were not 
specifically developed to understand cannabis-related respiratory symptoms, and the questions 
used in the current study evaluated symptom severity, instead of symptom frequency. At the time 
of study development and data collection, there were no available instruments that met our two 
most important needs: an instrument that 1) measured specifically acute cannabis-related 
respiratory symptoms and 2) contained few questions, which would be less burdensome for 
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participants. The three respiratory symptom questions used here (i.e., severity of 
coughing/wheezing, throat irritation, and phlegm/chest mucus) originated from EMA studies 
related to understanding asthma symptoms (Everhart et al., 2010; Nazarian et al., 2006). These 
items were chosen based on their successful use in previous EMA studies (Everhart et al., 2010; 
Nazarian et al., 2006), their brevity, and the finding that these same symptoms (i.e., cough, 
phlegm production, and wheeze) had been reported previously among cannabis users over time 
(Ribeiro & Ind, 2016). However, a more comprehensive instrument with questions regarding 
severity and frequency of commonly reported negative respiratory symptoms from cannabis use 
(including cough, phlegm production, shortness of breath, throat irritation, and wheeze) may be 
needed for future studies. Further, these results highlight a need for the development of valid and 
reliable instruments, which measure specifically acute cannabis-related negative respiratory 
symptom severity and frequency in order to understand more fully the health effects of cannabis 
use.  
It was hypothesized that those who used combusted cannabis administration methods at 
the highest frequencies would report the highest respiratory symptoms relative to the 
combination cannabis administration method sub-group. Results indicated that cannabis-related 
respiratory symptoms did not differ across cannabis administration method sub-group nor 
cannabis hits frequency sub-group. Although this finding is surprising, results from the current 
study indicated that cannabis-related respiratory symptoms were reported among our sample, 
albeit respiratory symptom severity was low (untransformed median = 1.00, actual range = 0 – 
16, possible range = 0 – 18). As such, these data indicate that there was similar respiratory 
symptom severity among heavy cannabis users, regardless of use frequency and administration 
method (with the exception of edibles, which were not included in analyses for this study). To 
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contextualize these results with other populations, an EMA study was conducted in 2006 in 
which people with asthma reported how bad their coughing and wheezing was during a 1-week 
period (Nazarian et al., 2006). Similar to the current study, the respiratory question scale ranged 
from 0 (not at all) to 6 (extremely). Results indicated that among adult asthma patients, the 
average respiratory score was 3.60 (SD = 3.59; Nazarian et al., 2006). In sum, results from the 
current study and from previous literature indicate that respiratory symptoms among cannabis 
users are relatively low. More research is needed to further contextualize the results from the 
current study. For example, future research should identify subjective respiratory symptoms of 
electronic cigarettes with and without nicotine and other inhaled substances, relative to cannabis-
related respiratory symptoms.  
There are several implications for the finding that heavy cannabis users reported some 
negative respiratory effects from using cannabis, regardless of the inhaled administration method 
and use frequency among this group. These results can be useful for cannabis interventionists, 
public health officials, and policymakers. For interventionists, these results indicate that heavy 
cannabis users (those who use greater than 5 days per week) exhibit some acute negative 
respiratory symptoms as a result of their cannabis use. Therefore, heavy cannabis users in 
particular may be a target group for cannabis cessation treatment, with the goal of diminishing 
the risk of negative respiratory effects from their cannabis use. Although future studies should 
examine whether light cannabis users (those who use cannabis less frequently than 5 days per 
week) report any respiratory symptoms as a result of their cannabis use. Interventionists would 
benefit from understanding which groups of cannabis users are most in need of their services. 
Current study results may serve as an impetus for public health officials to investigate the use of 
edibles as a potential harm reduction strategy, as this method of administration should have no 
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negative respiratory effects due to the oral route of administration. However, more research is 
needed to understand fully the health risks associated with edible use (e.g., accidental 
consumption of more than intended [Barrus et al., 2016; Hudak, Severn, & Nordstrom, 2015 
Lewis et al., 2020]). Another harm reduction strategy related to these findings for negative 
respiratory symptoms could involve the use financial incentives (e.g., discounts, price caps, etc.) 
to consumers to purchase or manufacturers/retailers to sell cannabis administration methods that 
do not cause respiratory harm, such as edibles. These incentives could be enforced at a local or 
state-level where cannabis sales are legal. Lastly, these results also warrant further investigation 
of other possible factors related to respiratory symptoms or respiratory health among cannabis 
users, including co-use of other inhaled products (e.g., cigarettes or nicotine vaping), cannabis 
forms (e.g., dried cannabis vs. concentrates), and other cannabis constituents (e.g., contaminants 
such as mold or other cannabinoids). Importantly, although the US Centers for Disease Control 
and Prevention identified that the cannabis concentrate additive, vitamin E acetate, was largely 
responsible for the EVALI outbreak in 2019, unanswered questions still remain regarding the 
potential negative effects of inhaling other cannabis concentrate additives on pulmonary health 
(Centers for Disease Control and Prevention, 2019).  
There were several other unexpected findings from the current study including main 
effects of week and interactions of week by day of week. There was a main effect of week for 
respiratory symptoms, which were higher during week 1 compared to week 2 and a main effect 
of week for number of cannabis administration methods used, which shared a similar pattern 
(e.g., higher reports during week 1 compared to week 2). These results were unexpected and 
have not been reported or observed in previous literature. There is a possibility that these main 
effects of week may diminish if four weeks of EMA data were collected. This same explanation 
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is applicable for the interactions of week by day of week observed in the current study. Across 
study results, there were interactions of week by day of week observed for cannabis use 
frequency, number of cannabis administration methods used, and cannabis-related intoxication 
symptoms. Among these three previous outcomes, two similar patterns emerged. There were 
higher reports of cannabis use frequency, number of cannabis administration methods used, and 
cannabis-related intoxication symptoms reported on Thursday of week 1 compared to week 2. 
There were also lower reports of cannabis use frequency, number of cannabis administration 
methods used, and cannabis-related intoxication symptoms reported on Sunday of week 1 
compared to week 2. One possible reason for higher reports on Sunday of week 2 compared to 
week 1 is an over-reporting from participants on the final day of data collection. Higher reports 
at the end of the study compared to the beginning of the study also could be a result of multiple 
sources of bias. Subject bias is when, instead of research participants responding or acting in a 
true manner, the participants act or respond in a way that they think is helpful to the research 
goal (Lester, 1969; McCambridge, Kypri, & Elbourne, 2014). Another bias that may have 
affected study results is reactivity. As a result of being observed for the research study, 
participants may have altered their normal patterns of behavior in the second week due to the 
observations in the first week of data collection.  
 There were several limitations to the current study. One limitation to the current study 
was the geographical area where the study was conducted. The data was collected at one study 
site in the Mid-Atlantic US region, in a US state where cannabis was illegal to use recreationally 
but was permitted to use for limited medicinal purposes. As such, current study results may only 
represent a small sub-group of cannabis users. If the study were to have taken place in a legalized 
cannabis policy environment where different types of cannabis products and administration 
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methods are easier to access, we may have recruited more cannabis users who exclusively used 
non-combusted administration methods, and we may have been able to conduct our intended 
analyses for Aim 2. Another limitation to the current study was the spread of the infectious virus, 
SARS-CoV-2 (COVID-19), during data collection. Data was collected over a two-month period 
from the end of January 2020 to the end of March 2020, and the first reported cases of COVID-
19 in the geographic area occurred during early March. Therefore, COVID-19 could have 
affected 11 participants who were currently engaged in data collection during this time. Another 
limitation to the current study was that participants who used other illicit substances in the past 
30 days were excluded from the study, and study results indicated that many users who were 
excluded were more dependent on cannabis, had used cannabis for a longer period of time, and 
were older than the sample included in the study. Therefore, the excluded group of participants 
was unique and warrants further examination. Future studies, which include participants who 
recently used other illicit substances, may reveal how other illicit substance and cannabis use 
patterns interact, as well as identify potential health risks related to the use of multiple 
substances. Another limitation to the current study was the inability to meet the intended sample 
size to detect day of week and time of day effects. There was sufficient power (0.90) to detect a 
moderate effect for time of day. However, there was insufficient power to detect a moderate 
effect for day of week (related to Aim 1); however, the use of a longer data collection period 
(e.g., four weeks) may offset the need for a larger sample size. Another limitation was the use of 
text message-based EMA, as opposed to other types of EMA, such as Interactive Voice 
Response or paper diaries. We encountered some problems with sending text messages to 
participants (e.g., technological issues and failed message deliveries). The use of text message-
based EMA also limited our recruitment to participants who had cellular data capabilities on 
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their cell phones. The inability to use the frequency of edible use data during analysis was 
another limitation. For the current study, cannabis use frequency was measured in hits, and 
edibles use frequency was quantified in number of edibles consumed. Hits frequency and number 
of edibles consumed are not synonymous measures. Hits are inhaled, whereas edibles are 
ingested. This difference in consumption would have affected the main outcomes of the study 
(i.e., respiratory and intoxication symptoms). Previous research indicates cannabis consumed 
orally is associated with delayed intoxication onset and stronger intoxication effects compared to 
inhaled cannabis (Schlienz et al., 2020; Spindle et al., 2018). As such, the choice was made to 
remove the frequency of edible use data from the current analyses. However, one way to 
examine cannabis edibles and inhaled administration methods and intoxication effects in the 
same study would be to gather samples of participants’ cannabis products and test the samples 
for THC concentration. Understanding THC concentration across products would provide a 
common variable to compare with subjective intoxication effects associated with various 
cannabis use behaviors among cannabis users.  
Conclusions 
In sum, daily cannabis use patterns and related acute health effects are not well 
understood. Results from the current study indicated that cannabis use frequency, number of 
cannabis administration methods used, and intoxication symptoms were highest or most severe 
during the evenings, which has implications for cannabis interventionists. Intoxication symptoms 
were higher among high frequency combination administration method users compared to high 
frequency combusted administration method users. Future research should measure cannabis-
related intoxication effects in different ways using biological and behavioral measures in clinical 
and natural settings. Finally, results indicated that cannabis-related respiratory symptoms were 
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similar across heavy cannabis users, regardless of use frequency or administration method used. 
These results are informative for interventionists, public health officials, and policymakers. More 
research is needed to address gaps in knowledge regarding cannabis use behaviors and the effects 
on intoxication and respiratory symptoms.  
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Appendix A. Aim 1 untransformed, transformed, and estimated marginal means and standard 
deviations or standard errors for Models 1-4.  
 
 
 Model 1: Cannabis hits frequency 
Model 2: Number of cannabis administration 
methods used 
 
Untransformed 
M (SD) 
Transformed 
M (SD) 
Estimated 
marginal M 
(SE) 
Untransformed 
M (SD) 
Transformed 
M (SD) 
Estimated 
marginal M 
(SE) 
Time of day       
Morning 3.52 (5.52) 1.25 (1.40) 1.26 (0.14) 0.63 (0.71) 0.56 (0.56) 0.56 (0.05) 
Afternoon 2.26 (3.86) 0.93 (1.18) 0.95 (0.14) 0.48 (0.58) 0.46 (0.52) 0.46 (0.05) 
Evening 3.62 (4.83) 1.41 (1.28) 1.42 (0.14) 0.71 (0.62) 0.66 (0.52) 0.66 (0.05) 
Day of week       
Monday 3.55 (5.23) 1.31 (1.36) 1.35 (0.16) 0.66 (0.66) 0.61 (0.54) 0.61 (0.06) 
Tuesday 2.57 (4.14) 1.05 (1.22) 1.07 (0.16) 0.57 (0.64) 0.53 (0.54) 0.53 (0.06) 
Wednesday 2.91 (4.56) 1.17 (1.25) 1.20 (0.16) 0.61 (0.62) 0.57 (0.54) 0.57 (0.06) 
Thursday 2.79 (4.19) 1.13 (1.23) 1.15 (0.16) 0.61 (0.67) 0.55 (0.55) 0.56 (0.06) 
Friday 3.13 (4.67) 1.21 (1.30) 1.25 (0.16) 0.59 (0.65) 0.55 (0.54) 0.57 (0.06) 
Saturday 3.81 (5.71) 1.34 (1.43) 1.33 (0.16) 0.64 (0.69) 0.58 (0.55) 0.58 (0.06) 
Sunday 3.02 (4.84) 1.14 (1.31) 1.11 (0.16) 0.54 (0.59) 0.52 (0.53) 0.51 (0.06) 
Week       
Week 1 3.20 (4.60) 1.25 (1.28) 1.26 (0.14) 0.64 (0.64) 0.59 (0.54) 0.59 (0.05) 
Week 2 3.02 (5.00) 1.13 (1.32) 1.16 (0.14) 0.57 (0.65) 0.52 (0.54) 0.53 (0.05) 
Day of week X week       
Week 1 
Monday 4.34 (6.00) 1.51 (1.44) 1.56 (0.18) 0.76 (0.70) 0.68 (0.55) 0.68 (0.07) 
Tuesday 2.54 (3.14) 1.15 (1.11) 1.18 (0.18) 0.69 (0.69) 0.62 (0.56) 0.62 (0.07) 
Wednesday 3.05 (4.43) 1.25 (1.23) 1.27 (0.18) 0.68 (0.65) 0.62 (0.55) 0.62 (0.07) 
Thursday 3.31 (4.26) 1.33 (1.25) 1.35 (0.18) 0.71 (0.66) 0.65 (0.54) 0.65 (0.07) 
Friday 3.01 (4.03) 1.23 (1.23) 1.25 (0.18) 0.60 (0.59) 0.57 (0.53) 0.57 (0.07) 
Saturday 3.69 (5.37) 1.33 (1.40) 1.31 (0.18) 0.61 (0.62) 0.57 (0.54) 0.56 (0.07) 
Sunday 2.51 (4.39) 0.95 (1.28) 0.91 (0.18) 0.44 (0.55) 0.42 (0.51) 0.41 (0.07) 
Week 2 
Monday 2.81 (4.28) 1.12 (1.26) 1.14 (0.18) 0.57 (0.62) 0.54 (0.53) 0.54 (0.07) 
Tuesday 2.61 (4.96) 0.95 (1.31) 0.96 (0.18) 0.45 (0.55) 0.43 (0.51) 0.43 (0.07) 
Wednesday 2.76 (4.73) 1.08 (1.27) 1.13 (0.18) 0.53 (0.58) 0.51 (0.53) 0.52 (0.07) 
Thursday 2.25 (4.06) 0.92 (1.20) 0.95 (0.19) 0.51 (0.67) 0.46 (0.55) 0.46 (0.07) 
Friday 3.26 (5.31) 1.18 (1.37) 1.26 (0.19) 0.59 (0.71) 0.53 (0.56) 0.56 (0.07) 
Saturday 3.93 (6.06) 1.35 (1.46) 1.36 (0.18) 0.67 (0.76) 0.59 (0.58) 0.59 (0.07) 
Sunday 3.52 (5.23) 1.33 (1.33) 1.32 (0.18) 0.64 (0.61) 0.61 (0.52) 0.60 (0.07) 
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Appendix A (continued). Aim 1 untransformed, transformed, and estimated marginal means and 
standard deviations or standard errors for Models 1-4.  
Note: “M” indicates mean, “SD” indicates standard deviation, and “SE” indicates standard error.  
 
 
 Model 3: Intoxication scores Model 4: Respiratory scores 
 
Untransformed 
M (SD) 
Transformed 
M (SD) 
Estimated 
marginal M 
(SE) 
Untransformed 
M (SD) 
Transformed 
M (SD) 
Estimated 
marginal M 
(SE) 
Time of day       
Morning 0.89 (1.63) 0.49 (0.81) 0.50 (0.09) 2.22 (3.15) 1.03 (1.08) 1.03 (0.15) 
Afternoon 1.28 (1.88) 0.69 (0.89) 0.70 (0.09) 1.87 (2.77) 0.91 (1.02) 0.92 (0.15) 
Evening 2.10 (2.26) 1.06 (1.00) 1.06 (0.09) 2.09 (2.89) 1.00 (1.04) 1.02 (0.15) 
Day of week       
Monday 1.27 (1.80) 0.71 (0.88) 0.72 (0.10) 2.05 (2.86) 1.01 (1.02) 1.02 (0.15) 
Tuesday 1.44 (2.16) 0.72 (0.96) 0.72 (0.10) 2.12 (2.98) 1.02 (1.05) 1.03 (0.16) 
Wednesday 1.53 (2.11) 0.79 (0.96) 0.79 (0.10) 2.13 (2.91) 1.02 (1.05) 1.04 (0.15) 
Thursday 1.32 (1.84) 0.72 (0.90) 0.72 (0.11) 2.04 (2.85) 0.99 (1.03) 1.02 (0.16) 
Friday 1.69 (2.16) 0.87 (0.97) 0.88 (0.11) 2.17 (3.10) 1.01 (1.07) 1.00 (0.16) 
Saturday 1.45 (2.04) 0.76 (0.94) 0.75 (0.11) 2.20 (3.19) 0.99 (1.11) 0.97 (0.16) 
Sunday 1.31 (1.92) 0.71 (0.91) 0.69 (0.11) 1.65 (2.66) 0.81 (1.00) 0.82 (0.16) 
Week       
Week 1 1.46 (2.03) 0.77 (0.93) 0.77 (0.09) 2.12 (2.70) 1.06 (1.00) 1.07 (0.15) 
Week 2 1.40 (2.00) 0.74 (0.93) 0.74 (0.09) 1.98 (3.16) 0.89 (1.09) 0.91 (0.15) 
Day of week X week       
Week 1 
Monday 1.16 (1.61) 0.69 (0.84) 0.71 (0.12) 2.18 (2.76) 1.11 (0.98) 1.12 (0.17) 
Tuesday 1.47 (2.01) 0.77 (0.94) 0.77 (0.12) 2.27 (2.67) 1.13 (1.00) 1.16 (0.17) 
Wednesday 1.49 (2.17) 0.75 (0.97) 0.76 (0.12) 2.05 (2.43) 1.05 (0.98) 1.06 (0.17) 
Thursday 1.63 (1.91) 0.89 (0.93) 0.88 (0.13) 2.45 (2.76) 1.22 (0.98) 1.24 (0.17) 
Friday 1.87 (2.26) 0.95 (0.99) 0.96 (0.12) 2.26 (2.94) 1.10 (1.03) 1.09 (0.17) 
Saturday 1.52 (2.21) 0.78 (0.96) 0.75 (0.12) 2.01 (2.75) 1.01 (1.01) 1.01 (0.17) 
Sunday 1.07 (1.89) 0.55 (0.88) 0.54 (0.12) 1.65 (2.60) 0.82 (0.99) 0.79 (0.17) 
Week 2 
Monday 1.38 (1.97) 0.72 (0.93) 0.73 (0.12) 1.92 (2.95) 0.92 (1.05) 0.93 (0.17) 
Tuesday 1.41 (2.31) 0.67 (0.99) 0.66 (0.12) 1.97 (3.28) 0.90 (1.09) 0.89 (0.17) 
Wednesday 1.58 (2.05) 0.84 (0.94) 0.83 (0.12) 2.22 (3.36) 0.98 (1.13) 1.03 (0.17) 
Thursday 1.01 (1.73) 0.55 (0.85) 0.56 (0.13) 1.61 (2.90) 0.76 (1.03) 0.81 (0.17) 
Friday 1.49 (2.04) 0.77 (0.95) 0.80 (0.13) 2.07 (3.28) 0.92 (1.12) 0.91 (0.17) 
Saturday 1.38 (1.87) 0.75 (0.92) 0.75 (0.12) 2.40 (3.61) 0.98 (1.21) 0.93 (0.17) 
Sunday 1.55 (1.93) 0.86 (0.91) 0.84 (0.12) 1.65 (2.74) 0.80 (1.01) 0.85 (0.17) 
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